Clinical trials tracker

Showing 943 trials

• PsilocybinNot yet recruiting
  Psilocybin After Trauma Surgery for Pain

  Phase 1Pain Management, Postoperative Pain70 participantsStart 2027-12

  Trent EmerickUnited StatesNCT07406828

• PsilocybinNot yet recruiting
  Psilocybin for Methamphetamine Use Disorder

  Phase 2Methamphetamine Use Disorder42 participantsStart 2027-02

  Peter HendricksUnited StatesNCT07774702

• PsilocybinNot yet recruiting
  Group PACBT for Depression

  Phase 2Depression - Major Depressive Disorder, Psilocybin, Cognitive Behavioral Therapy30 participantsStart 2027-01

  University of California, Los AngelesUnited StatesNCT07566104

• PsilocybinNot yet recruiting
  ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder

  Phase 1Borderline Personality Disorder, Borderline Personality Pathology, Depressive Symptoms18 participantsStart 2026-12

  University of MinnesotaUnited StatesNCT07833761

• PsilocybinNot yet recruiting
  MLS101 Study in PMDD

  Phase 1Premenstrual Dysphoric Disorder ( PMDD), PMDD32 participantsStart 2026-12

  MycoMedica Life Sciences PBCNCT07818720

• PsilocybinNot yet recruiting
  Psilocybin-Assisted Psychotherapy for Veterans With PTSD

  Phase 2Posttraumatic Stress Disorder (PTSD)12 participantsStart 2026-12

  ARQ National Psychotrauma CentreNetherlandsNCT07792538

• PsilocybinNot yet recruiting
  Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life

  Phase 1Aging, Longevity, Biomarkers of Aging50 participantsStart 2026-12

  Charles RaisonUnited StatesNCT07719088

• KetamineNot yet recruiting
  Electrophysiologic Mechanisms of Ketamine Antidepressant Response

  Phase 2Epilepsy, Depressive Symptoms37 participantsStart 2026-12

  Emory UniversityUnited StatesNCT07768618

• KetamineNot yet recruiting
  Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression

  Phase 2Treatment Resistant Depression (TRD), Chronic Pain25 participantsStart 2026-12

  University of RochesterUnited StatesNCT07247006

• PsilocybinNot yet recruiting
  Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder

  Phase 2Alcohol Use Disorder36 participantsStart 2026-11

  Brigham and Women's HospitalUnited StatesNCT07296094

• PsilocybinNot yet recruiting
  NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy

  Phase 2Psilocybin, Neuropathy83 participantsStart 2026-11

  M.D. Anderson Cancer CenterUnited StatesNCT07227909

• PsilocybinRecruiting
  Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study

  Phase 1Chronic Pelvic Pain15 participantsStart 2026-11

  Oregon Health and Science UniversityUnited StatesNCT06988319

• PsilocybinNot yet recruiting
  Psilocybin Therapy for Methamphetamine Use Disorder and HIV

  Phase 2Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV)30 participantsStart 2026-11

  Nicky Mehtani, MD, MPHUnited StatesNCT07756736

• PsilocybinNot yet recruiting
  Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation

  Phase 1Phase I24 participantsStart 2026-11

  Brown UniversityUnited StatesNCT07818564

• MDMANot yet recruiting
  MDMA-AT for PTSD in Young Adults With Childhood Trauma

  Phase 2Posttraumatic Stress Disorder (PTSD)15 participantsStart 2026-10

  Jenna M. TraynorUnited StatesNCT07765693

• PsilocybinNot yet recruiting
  MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial

  Phase 2Advanced Cancer, Demoralization, Existential Distress60 participantsStart 2026-10

  University of CalgaryCanadaNCT07791901

• PsilocybinNot yet recruiting
  Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence

  Phase 2Post Traumatic Stress Disorder PTSD, Intimate Partner Violence (IPV)76 participantsStart 2026-10

  University of CalgaryCanadaNCT06885996

• PsilocybinNot yet recruiting
  Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin

  Phase 2Alzheimer's Disease200 participantsStart 2026-10

  National Institute on Aging (NIA)United StatesNCT07721467

• LSDNot yet recruiting
  Shortened LSD Intervention for Major Depressive Disorder

  Phase 1Major Depression Moderate, Major Depression Severe, Major Depression10 participantsStart 2026-10

  Johns Hopkins UniversityUnited StatesNCT07503002

• KetamineNot yet recruiting
  Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts

  Phase 4Major Depressive Disorder (MDD)12 participantsStart 2026-10

  New York State Psychiatric InstituteUnited StatesNCT07139106

• KetamineNot yet recruiting
  Oral and Sublingual Ketamine

  Phase 1Major Depression Severe10 participantsStart 2026-10

  Western University, CanadaNCT07683988

• PsilocybinNot yet recruiting
  Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain

  Phase 2Chronic Low Back Pain (CLBP), Physical Therapy, Psilocybin45 participantsStart 2026-10

  Yale UniversityUnited StatesNCT07306364

• MDMANot yet recruiting
  MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First Responders

  Phase 2Post-Traumatic Stress Disorder, Adjustment Disorders30 participantsStart 2026-10

  Nautilus SanctuaryUnited StatesNCT05455996

• KetamineNot yet recruiting
  A Study Comparing Oral Ketamine With Oral Midazolam for the Treatment of Major Depressive Episodes

  Phase 3Major Depressive Episode220 participantsStart 2026-10

  Jawaharlal Institute of Postgraduate Medical Education & ResearchIndiaNCT07839338

• KetamineNot yet recruiting
  Outcomes Registry After Ketamine Infusions for Chronic Pain: A Longitudinal Evaluation

  Chronic Pain, Ketamine800 participantsStart 2026-10

  Stanford UniversityUnited StatesNCT07648771

• PsilocybinRecruiting
  Psilocybin Efficacy With or Without Pimavanserin Pretreatment

  Phase 1 / Phase 2Mood (Psychological Function), Well Being, Mood20 participantsStart 2026-09

  Johns Hopkins UniversityUnited StatesNCT07610135

• PsilocybinNot yet recruiting
  Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids

  Phase 2Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm20 participantsStart 2026-09

  Roswell Park Cancer InstituteUnited StatesNCT06827054

• MDMARecruiting
  MDMA-assisted Therapy for Fibromyalgia

  Early phase 1Fibromyalgia20 participantsStart 2026-09

  Spaulding Rehabilitation HospitalUnited StatesNCT06066853

• PsilocybinNot yet recruiting
  Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial

  Phase 2Advanced Cancer, Stage IV Solid Tumor Cancer, Stage IV Sarcoma of Bone46 participantsStart 2026-09

  University Health Network, TorontoCanadaNCT07820033

• PsilocybinNot yet recruiting
  Psilocybin for Treatment of OCD-2

  Phase 1 / Phase 2Obsessive - Compulsive Disorder20 participantsStart 2026-09

  Francisco A MorenoUnited StatesNCT06992999

• PsilocybinNot yet recruiting
  The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.

  Phase 1Healthy Participants, Placebo - Control, Psilocybin50 participantsStart 2026-09

  Gabriella GobbiNCT07433452

• PsilocybinRecruiting
  Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD

  Phase 2Alcohol Use Disorder200 participantsStart 2026-09

  NYU Langone HealthUnited StatesNCT06349083

• DMTNot yet recruiting
  Neural Effects of Intravenous N,N-dimethyltryptamine (DMT)

  Phase 1Healthy Participants Study20 participantsStart 2026-09

  Jon DeanUnited StatesNCT07693257

• PsilocybinRecruiting
  Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

  Phase 2 / Phase 3PTSD - Post Traumatic Stress Disorder, PTSD, PTSD Symptoms300 participantsStart 2026-09

  COMPASS PathwaysUnited StatesNCT07570654

• PsilocybinNot yet recruiting
  The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function

  Phase 1 / Phase 2Healthy48 participantsStart 2026-09

  Manoj DossUnited StatesNCT07079852

• PsilocybinRecruiting
  Psilocybin as a Novel Therapy for Residual Anhedonia

  Phase 1Anhedonia, Emotional Blunting90 participantsStart 2026-09

  NYU Langone HealthUnited StatesNCT07607938

• PsilocybinNot yet recruiting
  Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study

  Phase 1Well-Being, Psychological, Psychedelic Experiences120 participantsStart 2026-09

  University of Wisconsin, MadisonUnited StatesNCT07360301

• KetamineNot yet recruiting
  Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression

  Phase 2 / Phase 3Treatment Resistant Depression, Major Depressive Disorder (MDD)60 participantsStart 2026-09

  The Royal's Institute of Mental Health ResearchCanadaNCT07801703

• PsilocybinNot yet recruiting
  The Effects of Psilocybin on Social Connectedness

  Phase 1Loneliness, Grief51 participantsStart 2026-08

  Yale UniversityUnited StatesNCT07693153

• PsilocybinNot yet recruiting
  Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies

  Phase 2PTSD, PTSD - Post Traumatic Stress Disorder, Major Depression150 participantsStart 2026-08

  University of New MexicoNCT07745569

• PsilocybinRecruiting
  Psilocybin-Assisted Therapy for Intergenerational Trauma

  Phase 2Psychological Stress, Depression, Anxiety100 participantsStart 2026-08

  Rachel YehudaUnited StatesNCT06899165

• KetamineRecruiting
  KALM-B: Ketamine-assisted Psychotherapy (KAP) to Lessen Morbidity After Burn Injury

  Phase 2PTSD and Trauma-related Symptoms12 participantsStart 2026-08

  Irma FlemingUnited StatesNCT07563296

• PsilocybinRecruiting
  Psilocybin Administration With 5-HT1a Blockade

  Early phase 1Psychedelic Effects in Healthy Volunteers18 participantsStart 2026-08

  Johns Hopkins UniversityUnited StatesNCT07565493

• KetamineRecruiting
  Biomarker-Guided Antidepressant Selection

  Phase 4Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD), rTMS27 participantsStart 2026-08

  Weill Medical College of Cornell UniversityUnited StatesNCT07680140

• PsilocybinRecruiting
  Psilocybin to Treat Depression in Spinal Cord Injury

  Phase 1 / Phase 2Spinal Cord Injury, Depression - Major Depressive Disorder, Veteran30 participantsStart 2026-08

  James J. Peters Veterans Affairs Medical CenterUnited StatesNCT07251491

• PsilocybinRecruiting
  Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

  Phase 3Major Depression240 participantsStart 2026-08

  VA Office of Research and DevelopmentUnited StatesNCT07226232

• PsilocybinNot yet recruiting
  Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder

  Phase 1 / Phase 2Treatment Resistant Depression, Substance Use Disorders50 participantsStart 2026-08

  Indiana UniversityUnited StatesNCT07499583

• DMTRecruiting
  Inhaled DMT for Major Depressive Disorder

  Phase 2MDD, Major Depressive Disorder (MDD), Major Depression140 participantsStart 2026-08

  Universidade Federal do Rio Grande do NorteBrazilNCT07562191

• PsilocybinNot yet recruiting
  Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)

  Early phase 1IBS - Irritable Bowel Syndrome10 participantsStart 2026-08

  NYU Langone HealthUnited StatesNCT06760533

• EsketamineNot yet recruiting
  Dexmedetomidine-Esketamine Combination on Depression and Anxiety After Laparoscopic Ureteral Reconstruction

  Phase 4Ureteral Stricture, Dexmedetomidine, Esketamine658 participantsStart 2026-08

  Peking University First HospitalChinaNCT07753772

• EsketamineRecruiting
  A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression

  Phase 3Depressive Disorder, Treatment-Resistant348 participantsStart 2026-07

  Janssen Research & Development, LLCJapan, Taiwan, United StatesNCT07716098

• PsilocybinRecruiting
  Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young Adults With Anorexia Nervosa

  Phase 2Anorexia Nervosa40 participantsStart 2026-07

  Region SkaneSwedenNCT07169747

• KetamineRecruiting
  Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)

  Phase 2Borderline Personality Disorder (BPD), Treatment-Resistant Major Depressive Disorder, Treatment-resistant Bipolar Depression120 participantsStart 2026-07

  Joshua RosenblatCanadaNCT07569198

• KetamineNot yet recruiting
  Intra-Sessional Autonomic Arc Detection in Ketamine-Assisted Therapy for PTSD: A Signal Characterisation Pilot Study

  Post-Traumatic Stress Disorder5 participantsStart 2026-07

  Adriaan Dirk van der WartCanadaNCT07614581

• PsilocybinRecruiting
  Psilocybin as a Treatment for Chronic Pain in Smokers

  Early phase 1Smokers With Chronic Pain10 participantsStart 2026-07

  Yale UniversityUnited StatesNCT07118332

• PsilocybinRecruiting
  Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression

  Phase 2Treatment-Resistant Depression40 participantsStart 2026-07

  Centre for Addiction and Mental HealthCanadaNCT07211438

• PsilocybinRecruiting
  Mindfulness-based Psilocybin Therapy for PTSD

  Phase 2Post Traumatic Stress Disorder, Depression - Major Depressive Disorder30 participantsStart 2026-07

  Anthony P KingUnited StatesNCT07104916

• AyahuascaRecruiting
  Effects of a Sigle Dose of Ayahuasca in Patients With Psychogenic Non-epileptic Seizures: an Open Label Clinical Trial

  Phase 1 / Phase 2Non Epileptic Seizures15 participantsStart 2026-07

  University of Sao PauloBrazilNCT07747324

• PsilocybinRecruiting
  The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

  Phase 2Depression, Parkinson's Disease (PD)40 participantsStart 2026-07

  Yale UniversityUnited StatesNCT07610369

• PsilocybinNot yet recruiting
  Study of Psilocybin Under Anesthesia Controlled by EEG

  Phase 2Major Depression10 participantsStart 2026-07

  Stanford UniversityUnited StatesNCT07479550

• MDMARecruiting
  MDMA-Assisted Massed Exposure Therapy for PTSD

  Phase 2Post Traumatic Stress Disorder200 participantsStart 2026-07

  Emory UniversityUnited StatesNCT07288151

• PsilocybinRecruiting
  Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)

  Phase 2Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD)112 participantsStart 2026-06

  Centre Hospitalier St AnneFranceNCT07210112

• PsilocybinRecruiting
  Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms

  Phase 3Alcohol Use Disorder, Depressive Sympotoms, Psilocybin172 participantsStart 2026-06

  Centre Hospitalier Universitaire de NīmesFranceNCT07638553

• MDMARecruiting
  MDMA Therapy in Veterans With PTSD

  Phase 2Post Traumatic Stress Disorder52 participantsStart 2026-06

  Sunstone MedicalUnited StatesNCT07569159

• PsilocybinRecruiting
  Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder

  Phase 2Bipolar II Depression90 participantsStart 2026-06

  Lakshmi N YathamCanadaNCT06943573

• PsilocybinRecruiting
  A Study of Psychedelics in Healthy Older Adults With Low Well-being

  Phase 1Anhedonia in Healthy Volunteers, Older Adults (50-90 Years)80 participantsStart 2026-06

  Jennifer MitchellUnited StatesNCT07386730

• LSDNot yet recruiting
  Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism

  Liver Cirrhosis140 participantsStart 2026-06

  Northern Jiangsu People's HospitalChinaNCT07490405

• EsketamineRecruiting
  Esketamine Versus Crisis Response Planning Versus Enhanced Treatment as Usual for Suicide Prevention: A Pragmatic Randomized Trial in a Brazilian Municipality (SAVE)

  Phase 4Suicide Prevention, Ketamine, Crisis Response Plan478 participantsStart 2026-06

  University of Sao PauloBrazilNCT07120477

• PsilocybinNot yet recruiting
  Psilocybin-Assisted Therapy as a Treatment for Depression

  Phase 2Depression50 participantsStart 2026-06

  Washington University School of MedicineUnited StatesNCT07582120

• PsilocybinNot yet recruiting
  Psilocybin-Assisted Therapy

  Phase 2PTSD150 participantsStart 2026-06

  Emory UniversityUnited StatesNCT07332143

• PsilocybinRecruiting
  Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD

  Phase 2Post Traumatic Stress Disorder, PTSD, Chronic PTSD15 participantsStart 2026-06

  Unity Health TorontoCanadaNCT06386003

• PsilocybinNot yet recruiting
  Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression

  Phase 2Depression, Anxiety72 participantsStart 2026-06

  University of WashingtonNCT07565909

• MDMANot yet recruiting
  Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls

  Autism Spectrum Disorder40 participantsStart 2026-06

  University Hospital, Basel, SwitzerlandSwitzerlandNCT07555132

• EsketamineNot yet recruiting
  Intranasal Esketamine-dexmedetomidine Combination and Postpartum Depression

  Phase 4Parturients, Depressive Symptoms, Esketamine164 participantsStart 2026-06

  Peking University First HospitalChinaNCT07639099

• PsilocybinRecruiting
  Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD

  Phase 2Post Traumatic Stress Disorder, PTSD70 participantsStart 2026-05

  Sunstone MedicalUnited StatesNCT06902974

• MDMARecruiting
  MDMA Assisted Therapy for BN

  Phase 1Bulimia Nervosa40 participantsStart 2026-05

  Icahn School of Medicine at Mount SinaiUnited StatesNCT07542145

• PsilocybinRecruiting
  Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.

  Phase 1Obsessive-Compulsive Disorder30 participantsStart 2026-05

  Francisco A MorenoUnited StatesNCT07347405

• MDMARecruiting
  MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder

  Phase 2 / Phase 3Post Traumatic Stress Disorder, Alcohol Use Disorder80 participantsStart 2026-05

  VA Office of Research and DevelopmentUnited StatesNCT07118839

• PsilocybinRecruiting
  Subjective Experience Following Psilocybin

  Phase 2Investigating the Importance of the Subjective Psychedelic Experience128 participantsStart 2026-05

  University of CalgaryCanadaNCT06768944

• KetamineRecruiting
  Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients

  Phase 2Critical Illness, Depressive Symptoms50 participantsStart 2026-05

  Hospital Italiano de Buenos AiresArgentina, United StatesNCT07639359

• KetamineRecruiting
  InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression

  Phase 3Treatment Resistant Depression31 participantsStart 2026-05

  Sunnybrook Health Sciences CentreCanadaNCT06781697

• PsilocybinRecruiting
  Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder

  Phase 1PTSD36 participantsStart 2026-05

  University of New MexicoUnited StatesNCT07506395

• PsilocybinNot yet recruiting
  Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy

  Phase 2Treatment-Resistant Major Depressive Disorder16 participantsStart 2026-05

  Kyle GreenwayCanadaNCT07373535

• KetamineNot yet recruiting
  Intraoperative Ketamine for Chronic Postoperative Pain After Open-Heart Surgery

  Cardiac Anaesthesia, Chronic Pain, Post Operative Pain, Chronic100 participantsStart 2026-04

  Bursa City HospitalTurkey (Türkiye)NCT07490457

• PsilocybinNot yet recruiting
  Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a Pilot Study

  Phase 2Gambling Disorder30 participantsStart 2026-04

  Nantes University HospitalFranceNCT07391332

• PsilocybinRecruiting
  Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer

  Phase 1Demoralization, Safety15 participantsStart 2026-04

  Gustavo VazquezCanadaNCT06818994

• PsilocybinRecruiting
  Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.

  Early phase 1Healthy Adults100 participantsStart 2026-04

  Pontifícia Universidade Católica do Rio de JaneiroBrazilNCT07732166

• PsilocybinRecruiting
  Safety and Tolerability Trial of Psilocybin in Healthy Older Adults

  Phase 1Healthy Volunteer, Older Adults (65-85 Years)40 participantsStart 2026-04

  University of Colorado, DenverUnited StatesNCT07516405

• PsilocybinRecruiting
  Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder

  Phase 3Major Depressive Disorder, Post-Traumatic Stress Disorder (PTSD)60 participantsStart 2026-04

  Khyber Medical University PeshawarPakistanNCT07703722

• KetamineRecruiting
  Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine

  Early phase 1Major Depressive Disorder (MDD)10 participantsStart 2026-04

  University of PennsylvaniaUnited StatesNCT06788249

• DMT5-MeO-DMTNot yet recruiting
  Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects

  Phase 1Healthy Adult12 participantsStart 2026-04

  GH Research Ireland LimitedUnited StatesNCT07540494

• DMT5-MeO-DMTRecruiting
  Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants

  Phase 15-methoxy-dimethyltryptamine (5-MeO-DMT)40 participantsStart 2026-03

  University Hospital, Basel, SwitzerlandSwitzerlandNCT07444788

• KetamineRecruiting
  Ketamine Assisted Psychotherapy for Treating Comorbid Chronic Pain and PTSD

  Phase 1 / Phase 2Chronic Pain, Posttraumatic Stress Disorder (PTSD)30 participantsStart 2026-03

  Dr. Yuliya KnyahnytskaCanadaNCT07009158

• MDMANot yet recruiting
  MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function

  Phase 1Pharmacokinetics, Hepatic Impairment16 participantsStart 2026-03

  Resilient PharmaceuticalsUnited StatesNCT03606538

• PsilocybinRecruiting
  Psilocybin for Prolonged Grief Disorder

  Early phase 1Prolonged Grief Disorder12 participantsStart 2026-03

  University of VirginiaUnited StatesNCT06724289

• MDMARecruiting
  Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants

  Phase 1Healhty20 participantsStart 2026-03

  University Hospital, Basel, SwitzerlandSwitzerlandNCT07494214

• LSDRecruiting
  Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD

  LSD Reaction24 participantsStart 2026-03

  University Hospital, Basel, SwitzerlandSwitzerlandNCT07309471

• KetamineRecruiting
  Ketamine for Veterans With Parkinson's Disease

  Phase 2Parkinson's Disease80 participantsStart 2026-03

  VA Office of Research and DevelopmentUnited StatesNCT06231563

• KetamineRecruiting
  The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain.

  Early phase 1Opioid-Refractory Chronic Cancer-Related Pain24 participantsStart 2026-03

  National and Kapodistrian University of AthensGreeceNCT07408193

• PsilocybinNot yet recruiting
  Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder

  Phase 2Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD)30 participantsStart 2026-03

  Centre for Addiction and Mental HealthCanadaNCT07405606

• MDMARecruiting
  MDMA-Assisted Therapy for Mental Healthcare Providers

  Phase 1Mental Wellbeing30 participantsStart 2026-02

  Rachel YehudaUnited StatesNCT07102576

• PsilocybinRecruiting
  Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability

  Phase 1Stroke, Chronic Stroke, Intracerebral Haemorrhage20 participantsStart 2026-02

  Johns Hopkins UniversityUnited StatesNCT07053917

• KetamineRecruiting
  Ketamine for Opioid Use Disorder

  Phase 2Opioid Use Disorder50 participantsStart 2026-02

  University of Maryland, BaltimoreUnited StatesNCT06943859

• EsketamineRecruiting
  Esketamine With or Without Integration Therapy for Treatment-Resistant Depression

  Phase 4Treatment-resistant Depression (TRD)20 participantsStart 2026-02

  University of Puerto RicoPuerto RicoNCT07369102

• KetamineNot yet recruiting
  Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement

  Phase 2Opioid Use Disorder88 participantsStart 2026-02

  University of California, San DiegoUnited StatesNCT07369089

• MDMARecruiting
  Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial

  Phase 2Chronic Neuropathic Pain50 participantsStart 2026-01

  Unity Health TorontoCanadaNCT07301632

• PsilocybinRecruiting
  Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)

  Phase 3Psychological Distress120 participantsStart 2026-01

  Bruyère Health Research Institute.CanadaNCT07063862

• LSDRecruiting
  LSD Treatment for Persons With Alcohol Use Disorder

  Phase 2Alcohol Use Disorder (AUD)128 participantsStart 2026-01

  Felix MuellerSwitzerlandNCT05474989

• KetamineRecruiting
  Pilot Study of RR-HNK in OCD

  Phase 1 / Phase 2Obsessive-Compulsive Disorder45 participantsStart 2026-01

  Carolyn RodriguezUnited StatesNCT06575075

• EsketamineNot yet recruiting
  Effect of Esketamine on Perioperative Negative Emotions in Breast Cancer Surgery Patients With Severe Depression

  Depression, Anxiety, S-ketamine242 participantsStart 2026-01

  Chinese PLA General HospitalNCT07374211

• EsketamineNot yet recruiting
  Effect of Continuous Intraoperative Esketamine Infusion on Perioperative Negative Emotions in Breast Cancer Surgery Patients With Mild-to-Severe Depression

  Depression, Anxiety, S-ketamine142 participantsStart 2026-01

  Chinese PLA General HospitalNCT07374198

• EsketamineNot yet recruiting
  Effect of Esketamine on Perioperative Negative Emotions in Patients Undergoing Breast Cancer Surgery

  Depression, Anxiety, S-ketamine218 participantsStart 2026-01

  Chinese PLA General HospitalChinaNCT07367542

• PsilocybinNot yet recruiting
  Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter

  Phase 2Stuttering25 participantsStart 2026-01

  NYU Langone HealthUnited StatesNCT07296328

• EsketamineRecruiting
  A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

  Phase 3Depressive Disorder, Major258 participantsStart 2026-01

  Janssen Research & Development, LLCBrazil, Hungary, Italy + 4 moreNCT07227454

• PsilocybinRecruiting
  RCT of Psilocybin-assisted CBT for Depression

  Phase 1 / Phase 2Major Depressive Diorder50 participantsStart 2026-01

  University of California, Los AngelesUnited StatesNCT07281352

• PsilocybinRecruiting
  Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer

  Phase 2Lung Non-Small Cell Carcinoma, Unipolar Depression10 participantsStart 2026-01

  Alan DavisUnited StatesNCT07216404

• MDMARecruiting
  Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events

  Phase 2PTSD168 participantsStart 2025-12

  Sheba Medical CenterIsraelNCT07469098

• PsilocybinRecruiting
  Psilocybin on Brain Mechanisms of Motivation in OUD

  Phase 2Opioid Use Disorder24 participantsStart 2025-12

  University of PennsylvaniaUnited StatesNCT06810310

• AyahuascaRecruiting
  Ayahuasca, Esketamine and Premenstrual Symptoms

  Healthy Women Volunteers20 participantsStart 2025-12

  University of Sao PauloBrazilNCT07317232

• AyahuascaRecruiting
  Ayahuasca, Esketamine and Body Image Perception

  Healthy Women Volunteers20 participantsStart 2025-12

  University of Sao PauloBrazilNCT07317219

• AyahuascaEsketamineRecruiting
  Ayahuasca, Esketamine and PTSD

  Phase 2Posttraumatic Stress Disorder (PTSD)10 participantsStart 2025-12

  University of Sao PauloBrazilNCT07317206

• KetamineNot yet recruiting
  Ketamine Biomarker Validation

  Phase 1Treatment Resistant Depression (TRD)20 participantsStart 2025-12

  Soterix MedicalUnited StatesNCT07307768

• PsilocybinRecruiting
  Psilocybin for Opioid Use Disorder (OUD)

  Phase 2Opioid Use Disorder480 participantsStart 2025-12

  NYU Langone HealthUnited StatesNCT06796062

• PsilocybinRecruiting
  Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers

  Phase 1Healthy Volunteers10 participantsStart 2025-12

  Hadassah Medical OrganizationIsraelNCT07079930

• KetamineNot yet recruiting
  Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL)

  Phase 1 / Phase 2Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD), Comorbidities and Coexisting Conditions20 participantsStart 2025-12

  South West Sydney Local Health DistrictAustraliaNCT07247370

• MDMARecruiting
  A Phase 2A Trial of DT402 for Autism Spectrum Disorder

  Phase 2Autism Spectrum Disorder, ASD20 participantsStart 2025-12

  Definium Therapeutics US, Inc.United StatesNCT07303907

• KetamineRecruiting
  Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression

  Phase 2Chronic Low Back Pain, Depression44 participantsStart 2025-12

  VA Office of Research and DevelopmentUnited StatesNCT06419439

• PsilocybinRecruiting
  Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression

  Phase 2Treatment Resistant Depression20 participantsStart 2025-12

  Beersheva Mental Health CenterIsraelNCT07183748

• EsketamineRecruiting
  Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study

  Early phase 1Esketamine, ECT, Depression220 participantsStart 2025-11

  Min SuChinaNCT07247968

• KetamineRecruiting
  Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients

  Phase 4Orthopedic Trauma Surgery Patients, Postoperative Pain, Opioid Use90 participantsStart 2025-11

  Texas Tech University Health Sciences CenterUnited StatesNCT06903819

• PsilocybinRecruiting
  Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects

  Phase 1Depression - Major Depressive Disorder, Anhedonia85 participantsStart 2025-11

  Medical University of ViennaAustriaNCT07490353

• PsilocybinRecruiting
  Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults

  Phase 1Aging40 participantsStart 2025-11

  University of California, BerkeleyUnited StatesNCT06367738

• PsilocybinRecruiting
  Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication

  Phase 2Opioid Dependence, Chronic Pain10 participantsStart 2025-10

  University of British ColumbiaCanadaNCT05585229

• PsilocybinRecruiting
  Wellcome Leap Psilocybin for OUD

  Phase 2Opioid Use Disorder36 participantsStart 2025-10

  Anna Rose Childress, Ph.D.United StatesNCT06786325

• PsilocybinRecruiting
  PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm

  Early phase 1Self Harm30 participantsStart 2025-10

  Imperial College LondonUnited KingdomNCT06798636

• PsilocybinRecruiting
  Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder

  Phase 2Adjustment Disorder, Adjustment Disorder With Anxious Mood, Cancer87 participantsStart 2025-10

  Psyence Australia Pty LtdAustraliaNCT07072728

• LSDNot yet recruiting
  Microdosing LSD in Women With Premenstrual Disorders

  PMS, PMDD150 participantsStart 2025-10

  Friederike HolzeSwitzerlandNCT07189299

• EsketamineRecruiting
  Virtual Reality-Based Mindfulness as an Adjunct to Treatment as Usual in Treatment-Resistant Depression

  Depression - Major Depressive Disorder, Depression Disorder, Depression Chronic30 participantsStart 2025-09

  Hospital Universitari Vall d'Hebron Research InstituteSpainNCT07422519

• PsilocybinMDMARecruiting
  Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)

  Phase 1Posttraumatic Stress Disorder40 participantsStart 2025-09

  Johns Hopkins UniversityUnited StatesNCT06989957

• EsketamineRecruiting
  The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia

  Fibromyalgia, Pregabalin, Esketamine92 participantsStart 2025-09

  Beijing Tiantan HospitalChinaNCT07230171

• MDMARecruiting
  MDMA in Borderline Personality Disorder

  Phase 2Borderline Personality Disorder10 participantsStart 2025-09

  Yale UniversityUnited StatesNCT06683014

• PsilocybinRecruiting
  PRoMiSS: Psilocybin and the Role of Music in Set and Setting

  Phase 1Psilocybin, Music Intervention100 participantsStart 2025-08

  Johns Hopkins UniversityUnited StatesNCT07180108

• PsilocybinRecruiting
  The RECAP2 Study: Midazolam and Psilocybin

  Phase 1Psilocybin60 participantsStart 2025-08

  University of Wisconsin, MadisonUnited StatesNCT06692192

• DMTRecruiting
  Antidepressant Response of DMT Masked With Propofol

  Major Depressive Disorder, Psychedelic Experiences112 participantsStart 2025-08

  University Hospital, Basel, SwitzerlandSwitzerlandNCT06927076

• DMTRecruiting
  The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)

  Phase 1Alcohol Use Disorder (AUD), Alcohol-Related Disorders, Alcohol Use63 participantsStart 2025-08

  Yale UniversityUnited StatesNCT06070649

• PsilocybinRecruiting
  Mindfulness-Assisted Psychedelic Therapy

  Phase 2Mental Health40 participantsStart 2025-07

  University of Southern CaliforniaUnited StatesNCT06233344

• KetamineRecruiting
  A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression

  Phase 1 / Phase 2Depression10 participantsStart 2025-07

  Juliana Zambrano, MD, MPHUnited StatesNCT06597695

• PsilocybinRecruiting
  Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD

  Early phase 1Post-Traumatic Stress Disorder, PTSD13 participantsStart 2025-07

  Tel-Aviv Sourasky Medical CenterIsraelNCT07737054

• PsilocybinRecruiting
  Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer

  Phase 2Caregiver Distress15 participantsStart 2025-07

  University Health Network, TorontoCanadaNCT07048743

• KetamineRecruiting
  Ketamine Augmentation of ECT in Treatment-Resistant Depression

  Phase 3Major Depressive Disorder, Treatment Resistant Depression30 participantsStart 2025-07

  Università Vita-Salute San RaffaeleItalyNCT07088380

• PsilocybinRecruiting
  Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

  Phase 2Bipolar II Disorder, Depression, Bipolar, Suicidality10 participantsStart 2025-07

  The University of Texas Health Science Center, HoustonUnited StatesNCT06706232

• PsilocybinRecruiting
  Psilocybin Therapy for Psychological Distress in Palliative Patients

  Phase 2COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis), MS (Multiple Sclerosis)108 participantsStart 2025-07

  University Medical Center GroningenCzechia, Denmark, Netherlands + 1 moreNCT06782724

• PsilocybinKetamineRecruiting
  Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial

  Phase 2Alcohol Use Disorder, Alcohol Dependence, Alcohol Abuse80 participantsStart 2025-06

  University of IowaUnited StatesNCT06405607

• MDMARecruiting
  Dose Optimization of MDMA-Assisted Therapy for PTSD

  Phase 2Posttraumatic Stress Disorder60 participantsStart 2025-06

  Bronx VA Medical CenterUnited StatesNCT06418178

• KetamineRecruiting
  Ketamine and Neurofeedback as Combined Therapeutic Interventions to Target Glutamatergic Neurotransmission in Alcohol Use Disorder

  Phase 2Alcohol Abuse/Dependence, Alcohol Use Disorder (AUD), Alcoholism75 participantsStart 2025-06

  Dr. med. Marcus HerdenerSwitzerlandNCT06969937

• PsilocybinRecruiting
  A Randomized Neuroimaging Trial of Psilocybin in Depression

  Phase 2Depressive Disorder, Major Depressive Disorder50 participantsStart 2025-05

  Sunnybrook Health Sciences CentreCanadaNCT06072898

• PsilocybinRecruiting
  Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)

  Phase 1Opioid Use Disorder12 participantsStart 2025-05

  Yale UniversityUnited StatesNCT06160284

• PsilocybinRecruiting
  Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy

  Phase 1Persisting Symptoms After Concussion40 participantsStart 2025-05

  University of CalgaryCanadaNCT06615908

• PsilocybinRecruiting
  TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

  Phase 2Depression, Anxiety, Cancer20 participantsStart 2025-05

  M.D. Anderson Cancer CenterUnited StatesNCT06801041

• PsilocybinRecruiting
  Mechanistic Studies of Psilocybin in Headache Disorders

  Early phase 1Migraine50 participantsStart 2025-05

  Yale UniversityUnited StatesNCT06464367

• PsilocybinRecruiting
  Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder

  Phase 2Generalized Anxiety Disorder (GAD)50 participantsStart 2025-05

  Claudio N SoaresCanadaNCT06969170

• EsketamineRecruiting
  Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments

  Depression, OCD, Anxiety Depression12000 participantsStart 2025-05

  NeuroneticsUnited StatesNCT06997549

• PsilocybinRecruiting
  Investigation to Understand and Optimize Psilocybin

  Phase 2Depression141 participantsStart 2025-05

  Charles RaisonUnited StatesNCT06512194

• KetamineRecruiting
  ACT_for Alcohol Use Disorder and Depression

  Depression - Major Depressive Disorder, Alcohol Use Disorder30 participantsStart 2025-05

  Centre hospitalier de l'Université de Montréal (CHUM)CanadaNCT06620276

• KetamineNot yet recruiting
  Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents

  Phase 3Depressive Disorder, Suicidal Ideas60 participantsStart 2025-05

  Federal University of São PauloNCT06957704

• EsketamineRecruiting
  Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

  Phase 3Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression1254 participantsStart 2025-04

  Dr. Inge WinterIsraelNCT05603104

• PsilocybinRecruiting
  Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)

  Phase 2Treatment Resistant Depression12 participantsStart 2025-04

  Centre for Addiction and Mental HealthCanadaNCT06512220

• PsilocybinRecruiting
  Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness

  Phase 1Healthy16 participantsStart 2025-04

  University Hospital, Basel, SwitzerlandSwitzerlandNCT06796361

• LSDRecruiting
  LSD to Improve Cluster Headache Impact Trial

  Phase 2Chronic Cluster Headache65 participantsStart 2025-04

  Radboud University Medical CenterNetherlandsNCT05477459

• PsilocybinRecruiting
  Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

  Early phase 1Amyotrophic Lateral Sclerosis24 participantsStart 2025-04

  Johns Hopkins UniversityUnited StatesNCT06656702

• KetamineRecruiting
  Understanding and Treating Suicidal Ideation With Ketamine

  Phase 2 / Phase 3Suicidal Ideation, Major Depressive Disorder (MDD)36 participantsStart 2025-04

  The Royal's Institute of Mental Health ResearchCanadaNCT06891300

• PsilocybinRecruiting
  Psilocybin for Methamphetamine Addiction

  Early phase 1Methamphetamine Use Disorder20 participantsStart 2025-04

  Kevin MurnaneUnited StatesNCT06899594

• PsilocybinLSDRecruiting
  Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants

  Phase 1Healthy24 participantsStart 2025-04

  University Hospital, Basel, SwitzerlandSwitzerlandNCT06899334

• PsilocybinRecruiting
  Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)

  Phase 2Treatment Resistant Depression, Chronic Pain16 participantsStart 2025-04

  Centre for Addiction and Mental HealthCanadaNCT06518720

• EsketamineRecruiting
  Esketamine Combined Pulsed Radiofrequency for Acute/Subacute Zoster-associated Trigeminal Neuralgia

  Zoster; Herpes, Trigeminal Neuralgia (Etiology)174 participantsStart 2025-04

  Beijing Tiantan HospitalChinaNCT06890897

• EsketamineNot yet recruiting
  Esketamine Combined With PRF for Trigeminal Postherpetic Neuralgia

  Postherpetic; Neuralgia, Trigeminal (Etiology)174 participantsStart 2025-04

  Beijing Tiantan HospitalChinaNCT06914180

• EsketamineNot yet recruiting
  Esketamine Combined With PRF of DRG for Postherpetic Neuralgia

  Postherpetic Neuralgia186 participantsStart 2025-04

  Beijing Tiantan HospitalChinaNCT06914193

• EsketamineRecruiting
  Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia

  Postherpetic Neuralgia150 participantsStart 2025-04

  Beijing Tiantan HospitalChinaNCT06896994

• EsketamineNot yet recruiting
  Esketamine Combined With PRF of DRG for Acute/Subacute Zoster-associated Pain

  Herpes Zoster184 participantsStart 2025-04

  Beijing Tiantan HospitalChinaNCT06914206

• KetamineNot yet recruiting
  Effects of Intranasal Ketamine on Depression and Anxiety in Palliative Care Cancer Patients

  Early phase 1Depressive Symptoms Mild to Moderate in Severity, Anxiety, Quality of Life (QOL)100 participantsStart 2025-04

  University of ZurichSwitzerlandNCT06665568

• PsilocybinRecruiting
  Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN

  Phase 2Chronic Neuropathic Pain, Pain Management30 participantsStart 2025-03

  Unity Health TorontoCanadaNCT06731335

• PsilocybinRecruiting
  Digital Intervention for Psychedelic Preparation (DIPP): Comparing Meditation and Music-Based Programs

  Phase 1Healthy40 participantsStart 2025-03

  University College, LondonUnited KingdomNCT06815653

• MDMARecruiting
  MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder

  Phase 2Post Traumatic Stress Disorder40 participantsStart 2025-03

  Stephen Robert MarderUnited StatesNCT05790239

• KetamineRecruiting
  Analgesic Efficacy of Intravenous Ketamine as a Continuous Infusion vs PCA in the Management of Acute Postoperative Pain in Major Orthopedic Surgery.

  Phase 4Pain, Postoperative, Opioid Use, Major Surgery120 participantsStart 2025-03

  Universidad de AntioquiaColombiaNCT06774274

• PsilocybinRecruiting
  Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder

  Phase 2Major Depressive Disorder60 participantsStart 2025-02

  Icahn School of Medicine at Mount SinaiUnited StatesNCT06592833

• MDMARecruiting
  MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder

  Phase 2PTSD30 participantsStart 2025-02

  Patricia SuppesUnited StatesNCT05837845

• KetamineRecruiting
  Intravenous Ketamine for Treatment-Resistant Depression

  Phase 2Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)30 participantsStart 2025-02

  Mayo ClinicUnited StatesNCT06668571

• PsilocybinMDMADMTRecruiting
  Investigation of Psychedelic Effects in Psychoactive Substances

  Phase 1Psychedelic Effects in Healthy Volunteers50 participantsStart 2025-02

  Johns Hopkins UniversityUnited StatesNCT06772753

• PsilocybinRecruiting
  State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma

  Phase 2PTSD15 participantsStart 2025-01

  Baylor College of MedicineUnited StatesNCT06888128

• PsilocybinRecruiting
  The ENHANCE Study: taVNS and Psilocybin

  Phase 1Healthy, Psychedelic Experiences, Vagus Nerve Stimulation108 participantsStart 2025-01

  University of Wisconsin, MadisonUnited StatesNCT05866471

• MDMARecruiting
  Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls

  Central Diabetes Insipidus24 participantsStart 2025-01

  University Hospital, Basel, SwitzerlandSwitzerlandNCT06789705

• EsketamineRecruiting
  PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study

  Phase 3Depression400 participantsStart 2025-01

  Yale UniversityUnited StatesNCT06713616

• KetamineRecruiting
  Ketamine for Combined Depression and Alcohol Use Disorder

  Phase 1 / Phase 2Depression, Alcohol Use Disorder34 participantsStart 2025-01

  University Hospital of North NorwayNorwayNCT06090422

• PsilocybinRecruiting
  Pragmatic Trial of Psilocybin Therapy in Palliative Care

  Phase 2Demoralization100 participantsStart 2025-01

  Charles S. Grob, M.D.United StatesNCT05403086

• PsilocybinRecruiting
  Psilocybin-Assisted Therapy for Physician Well-Being and Burnout

  Phase 1 / Phase 2Burnout, Burnout, Healthcare Workers30 participantsStart 2025-01

  University of California, San DiegoUnited StatesNCT06814522

• PsilocybinRecruiting
  Psilocybin rTMS for Treatment Resistant Depression

  Phase 2Treatment Resistant Depression, MDD, Major Depressive Disorder100 participantsStart 2025-01

  University of Texas at AustinUnited StatesNCT06132178

• KetamineRecruiting
  Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression

  Phase 2Major Depressive Disorder70 participantsStart 2025-01

  Icahn School of Medicine at Mount SinaiUnited StatesNCT06559826

• EsketamineRecruiting
  Personalized DBS Targeting for Treating Depression

  Early phase 1Treatment-resistant Depression (TRD)5 participantsStart 2025-01

  Second Affiliated Hospital, Zhejiang University, School of MedicineChinaNCT06784388

• PsilocybinRecruiting
  Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe OCD

  Phase 2Obsessive-compulsive Disorder15 participantsStart 2024-11

  Beersheva Mental Health CenterIsraelNCT04882839

• PsilocybinRecruiting
  Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence

  Phase 1Breast Cancer, Ovarian Cancer20 participantsStart 2024-11

  University of Colorado, DenverUnited StatesNCT06430541

• PsilocybinRecruiting
  Study of Psilocybin for Anorexia in Young Adults

  Phase 2Anorexia Nervosa40 participantsStart 2024-11

  Marissa Raymond-Flesch, MD, MPHUnited StatesNCT06399263

• MDMARecruiting
  MDMA-Assisted CBCT for PTSD vs CBCT RCT

  Phase 2Post Traumatic Stress Disorder60 participantsStart 2024-11

  RemedyCanadaNCT06044675

• PsilocybinRecruiting
  Psilocybin-assisted Treatment for Cannabis Use Disorder

  Phase 1Cannabis Use Disorder12 participantsStart 2024-11

  Johns Hopkins UniversityUnited StatesNCT06660381

• KetamineRecruiting
  Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

  Phase 2Suicide, Depressive Disorder, Treatment-Resistant, Ketamine50 participantsStart 2024-11

  National Institute of Mental Health (NIMH)United StatesNCT06511908

• PsilocybinRecruiting
  Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers

  Phase 2Healthy Participants With Lower-than-average Mental Well-being120 participantsStart 2024-10

  Robin Carhart-Harris, PhD, MAUnited StatesNCT06626139

• KetamineRecruiting
  Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients

  Phase 3Major Depressive Episode60 participantsStart 2024-10

  Assistance Publique - Hôpitaux de ParisFranceNCT06508710

• PsilocybinRecruiting
  Open-Label Psilocybin Study in Transdiagnostic Population

  Phase 1Transdiagnostic, Depression - Major Depressive Disorder, Anxiety50 participantsStart 2024-10

  Yale UniversityUnited StatesNCT06442423

• KetamineRecruiting
  Nebulized Ketamine for the Treatment of Major Depressive Disorder

  Phase 3Severe Depression, Moderate Depression, Ketamine40 participantsStart 2024-10

  Theresa Jacob, PhD, MPHUnited StatesNCT06752759

• KetamineRecruiting
  The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD

  Phase 4Neuropathic Pain, PTSD30 participantsStart 2024-10

  Margaux M. Salas, PhDUnited StatesNCT06414356

• PsilocybinRecruiting
  Psilocybin in Cancer Pain Study

  Phase 2Opioid-Related Disorders, Pain Management, Pain Management and Care15 participantsStart 2024-09

  Yvan Beaussant, MD, MSciUnited StatesNCT06001749

• KetamineRecruiting
  (2R,6R)-Hydroxynorketamine for the Treatment of Neuropathic Pain

  Phase 1 / Phase 2Pain, Neuropathic25 participantsStart 2024-09

  Rush University Medical CenterUnited StatesNCT05864053

• PsilocybinRecruiting
  The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

  Phase 3Major Depressive Disorder20 participantsStart 2024-09

  Sharmin GhaznaviUnited StatesNCT06247839

• PsilocybinRecruiting
  Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression

  Phase 1 / Phase 2Depressive Disorder24 participantsStart 2024-09

  Federal University of Latin American IntegrationBrazilNCT06898606

• MDMARecruiting
  Tolerability of MDMA in Schizophrenia

  Phase 1 / Phase 2Schizophrenia20 participantsStart 2024-09

  Anya Bershad, MD, PhDUnited StatesNCT05770375

• KetamineRecruiting
  Imaging Depression in Parkinson's Disease

  Phase 2Parkinson's Disease, Major Depressive Disorder120 participantsStart 2024-09

  Yale UniversityUnited StatesNCT06402955

• EsketamineRecruiting
  The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

  Phase 3Major Depressive Disorder, Treatment Resistant Depression418 participantsStart 2024-08

  Dr. Inge WinterAustria, Germany, Greece + 3 moreNCT05973851

• PsilocybinRecruiting
  Psilocybin Therapy for Depression in Parkinson's Disease

  Phase 2Parkinson Disease, Depression60 participantsStart 2024-08

  Joshua Woolley, MD, PhDUnited StatesNCT06455293

• KetamineRecruiting
  Low-Dose Ketamine Infusion During Burn Wound Care

  Phase 4Burn, Pain, Dissociation140 participantsStart 2024-07

  University of TennesseeUnited StatesNCT06506565

• LSDRecruiting
  Lysergic Acid Diethylamide (LSD) in Palliative Care

  Phase 2Palliative Care, Pain, Anxiety60 participantsStart 2024-06

  University Hospital, Basel, SwitzerlandSwitzerlandNCT05883540

• EsketamineRecruiting
  Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression

  Phase 4Treatment Resistant Depression162 participantsStart 2024-06

  The George InstituteAustraliaNCT06278779

• PsilocybinRecruiting
  Psilocybin for Hospitalized Patients with Treatment-resistant Depression

  Phase 2Treatment Resistant Depression100 participantsStart 2024-05

  University Hospital, GhentBelgiumNCT06378229

• PsilocybinRecruiting
  The Impact of Psilocybin on Pain in Fibromyalgia Patients

  Fibromyalgia35 participantsStart 2024-05

  Maastricht UniversityNetherlandsNCT06368492

• KetamineRecruiting
  Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department

  Phase 1Suicide, Suicidal Ideation, Depression50 participantsStart 2024-05

  Lindsay Maguire, MDUnited StatesNCT06085937

• KetamineRecruiting
  Pharmacologic Treatment Augmentation in Chronic Depression

  Phase 2Major Depressive Disorder60 participantsStart 2024-04

  University Hospital TuebingenGermanyNCT06410599

• PsilocybinRecruiting
  Psilocybin in Chronic Low Back Pain and Depression

  Phase 1Chronic Low-back Pain, Depression40 participantsStart 2024-04

  Johns Hopkins UniversityUnited StatesNCT06355414

• PsilocybinRecruiting
  Cancer Related Major Depression Treated With a Single Dose of Psilocybin

  Phase 2MDD100 participantsStart 2024-04

  Section for Affective Disorders; Northern Stockholm PsychiatrySwedenNCT06319378

• PsilocybinRecruiting
  Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

  Phase 2Depression, Anxiety, Psilocybin-Assisted Psychotherapy, Advanced Cancer48 participantsStart 2024-04

  M.D. Anderson Cancer CenterUnited StatesNCT06200155

• MDMARecruiting
  MDMA for Co-occurring PTSD and OUD After Childbirth

  Phase 2Stress Disorders, Post-Traumatic, Opioid Use Disorder15 participantsStart 2024-04

  University of New MexicoUnited StatesNCT05219175

• PsilocybinRecruiting
  Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder

  Phase 2Alcohol Use Disorder, Alcoholism128 participantsStart 2024-03

  University of CalgaryCanadaNCT05995769

• PsilocybinRecruiting
  Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain

  Phase 1Perception Disorders80 participantsStart 2024-03

  University of California, BerkeleyUnited StatesNCT05265546

• EsketamineRecruiting
  Esketamine as Treatment for Chronic Pain Due to Endometriosis: a RCT Study

  Phase 3Endometriosis, Chronic Pelvic Pain Syndrome56 participantsStart 2024-03

  Reinier de Graaf GroepNetherlandsNCT06161805

• KetamineNot yet recruiting
  Ketamine Treatment for PTSD and MDD in TBI

  Phase 2PTSD, Post Traumatic Stress Disorder, Major Depressive Disorder, Traumatic Brain Injury40 participantsStart 2024-03

  Minneapolis Veterans Affairs Medical CenterUnited StatesNCT06228391

• KetamineRecruiting
  Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)

  Phase 2Obsessive-Compulsive Disorder150 participantsStart 2024-02

  Stanford UniversityUnited StatesNCT05940324

• MDMARecruiting
  Examining 3,4-methylenedioxymethamphetamine (MDMA) Effects on Psychological, Relational and Hyperarousal-Related Neural Reactivity Mechanisms in Veterans With PTSD and Moral Injury

  Phase 3PTSD, Post Traumatic Stress Disorder, Moral Injury60 participantsStart 2024-02

  Herzog HospitalIsraelNCT06394284

• PsilocybinRecruiting
  Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

  Phase 2Opioid Use Disorder90 participantsStart 2024-02

  Johns Hopkins UniversityUnited StatesNCT06067737

• KetamineRecruiting
  Ketamine and Neurofeedback-Training: Effects on Neuroplasticity in Cocaine Addiction

  Phase 2Cocaine Use Disorder, Cocaine Dependence120 participantsStart 2024-02

  Dr. med. Marcus HerdenerSwitzerlandNCT06125054

• KetamineRecruiting
  Neural Circuit Effects of Ketamine in Depression

  Phase 4Major Depressive Disorder120 participantsStart 2024-01

  Icahn School of Medicine at Mount SinaiUnited StatesNCT06213324

• EsketamineRecruiting
  The OBSERVE Protocol

  Major Depression Disorder450 participantsStart 2024-01

  Yale UniversityUnited StatesNCT06725277

• KetamineRecruiting
  i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial

  Phase 2Major Depressive Disorder, Suicide, Treatment Resistant Depression110 participantsStart 2024-01

  University Health Network, TorontoCanadaNCT06480500

• KetamineRecruiting
  Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression

  Phase 1Healthy, Major Depressive Disorder, Treatment Resistant Depression100 participantsStart 2024-01

  Texas A&M UniversityUnited StatesNCT06480201

• KetamineRecruiting
  IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED

  Phase 4Laceration of Skin, Anxiety, Discharge Time90 participantsStart 2023-11

  University of OklahomaUnited StatesNCT05934669

• PsilocybinRecruiting
  5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

  Phase 2Tobacco Use Disorder66 participantsStart 2023-11

  Johns Hopkins UniversityUnited StatesNCT05452772

• PsilocybinRecruiting
  Psilocybin-facilitated Treatment for Chronic Pain

  Early phase 1Fibromyalgia, Primary30 participantsStart 2023-11

  University of Alabama at BirminghamUnited StatesNCT05068791

• EsketamineRecruiting
  Positioning of Esketamine Treatment in the Real-world Management of Depression

  Phase 4Major Depressive Disorder162 participantsStart 2023-10

  Royal North Shore HospitalAustraliaNCT06103760

• KetamineRecruiting
  RIVER At Home Ketamine Protocols

  Chronic Condition, Chronic Pain, Chronic Disease50000 participantsStart 2023-10

  RIVER FoundationUnited StatesNCT06070766

• KetamineRecruiting
  Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

  Phase 1Depressive Disorder, Major, Post Traumatic Stress Disorder50 participantsStart 2023-09

  Yale UniversityUnited StatesNCT05915013

• MDMARecruiting
  Preliminary Effectiveness of Individual and Group MDMA-assisted Therapy for Israeli Veterans With PTSD and Moral Injury.

  Phase 2Post Traumatic Stress Disorder, Moral Injury, MDMA ('Ecstasy')60 participantsStart 2023-06

  HaEmek Medical Center, IsraelIsraelNCT05732155

• PsilocybinRecruiting
  Psilocybin Therapy in Advanced Cancer

  Phase 2 / Phase 3Advanced Cancer200 participantsStart 2023-05

  NYU Langone HealthUnited StatesNCT05398484

• EsketamineRecruiting
  Effect of Esketamine and Lidocaine on Postoperative Chronic Pain and Long-term Survival in Patients Undergoing Hepatectomy

  Postoperative Chronic Pain304 participantsStart 2023-05

  West China HospitalChinaNCT06778460

• KetamineRecruiting
  Oral Ketamine for Treatment of Vaso-Occlusive Pain

  Phase 3Vaso-occlusive Crisis10 participantsStart 2023-05

  Boston Children's HospitalUnited StatesNCT05378555

• KetamineRecruiting
  The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects

  Phase 2Depressive Disorder, Major Depressive Disorder, Bipolar Disorder30 participantsStart 2023-04

  Yale UniversityUnited StatesNCT05786066

• EsketamineRecruiting
  Metabolic Profiling of Esketamine Treatment in Depressive Disorder

  Major Depressive Disorder100 participantsStart 2023-04

  University of ZagrebCroatiaNCT07002684

• EsketamineRecruiting
  IV Ketamine vs. IN Esketamine for MDD TRD

  Treatment Resistant Depression80 participantsStart 2023-03

  Gustavo VazquezCanadaNCT06488586

• KetamineRecruiting
  Ketamine & Crisis Response Plan for Suicidal Ideation in the ED

  Phase 2 / Phase 3Suicide24 participantsStart 2023-01

  The University of Texas Health Science Center at San AntonioUnited StatesNCT05696691

• KetamineRecruiting
  Ketamine Treatment Plans for Chronic Conditions

  Chronic Pain, Depressive Disorder, Anxiety Disorders500 participantsStart 2023-01

  RIVER FoundationUnited StatesNCT06038409

• KetamineRecruiting
  Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine

  Early phase 1Major Depressive Disorder140 participantsStart 2022-11

  Emory UniversityUnited StatesNCT05327699

• EsketamineRecruiting
  Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression

  Depression and Quality of Life, Treatment Resistant Depression (TRD), Anhedonia100 participantsStart 2022-11

  Riccardo GuglielmoItalyNCT07146503

• EsketamineRecruiting
  Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression

  Phase 4Major Depressive Disorder100 participantsStart 2022-10

  Massachusetts General HospitalUnited StatesNCT05450432

• MDMARecruiting
  MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other

  Phase 2Cancer, Adjustment Disorders20 participantsStart 2022-10

  Sunstone MedicalUnited StatesNCT05584826

• KetamineRecruiting
  Ketamine Treatment of Youth Suicide Attempters

  Phase 3Suicide, Attempted60 participantsStart 2022-06

  Tatiana Falcone, MDUnited StatesNCT04763343

• KetamineRecruiting
  Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches

  Phase 3Chronic Daily Headache56 participantsStart 2022-06

  University Health Network, TorontoCanadaNCT05306899

• PsilocybinRecruiting
  Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

  Phase 1 / Phase 2Healthy30 participantsStart 2022-03

  Johns Hopkins UniversityUnited StatesNCT05301608

• KetamineRecruiting
  Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer

  Phase 1 / Phase 2Head and Neck Cancer, Locally Advanced Head and Neck Carcinoma64 participantsStart 2022-01

  Natalie LockneyUnited StatesNCT05156060

• PsilocybinRecruiting
  Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

  Early phase 1Depressive Symptoms, Depression, Alzheimer Disease20 participantsStart 2021-03

  Johns Hopkins UniversityUnited StatesNCT04123314

• PsilocybinRecruiting
  Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine

  Phase 1Opioid Use Disorder10 participantsStart 2021-01

  University of Wisconsin, MadisonUnited StatesNCT04161066

• EsketamineRecruiting
  University of Iowa Interventional Psychiatry Service Patient Registry

  Treatment Resistant Depression, Major Depressive Episode, Major Depression1000 participantsStart 2020-11

  Mark NiciuUnited StatesNCT04480918

• LSDRecruiting
  Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache

  Phase 2Cluster Headache30 participantsStart 2019-01

  University Hospital, Basel, SwitzerlandSwitzerlandNCT03781128

• KetamineRecruiting
  Dexmedetomidine and Ketamine in VATS Surgery

  Postoperative Pain, Opioid Use120 participantsStart 2018-02

  Ciusss de L'Est de l'Île de MontréalCanadaNCT03596424

• KetamineRecruiting
  ECT with Ketamine Anesthesia Vs High Intensity Ketamine with ECT Rescue for Treatment-Resistant Depression

  Phase 4Treatment Resistant Depression, Ketamine62 participantsStart 2017-09

  University of SaskatchewanCanadaNCT03272698

• KetamineRecruiting
  Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder

  Phase 1Healthy Volunteer, Major Depressive Disorder, Depression150 participantsStart 2017-05

  National Institute of Mental Health (NIMH)United StatesNCT03065335

• PsilocybinRecruiting
  The Neurobiological Effect of 5-HT2AR Modulation

  Phase 1Basic Science200 participantsStart 2017-03

  Gitte Moos KnudsenDenmarkNCT03289949

• KetamineRecruiting
  Neurobiology of Suicide

  Phase 2Healthy Volunteers, Depression325 participantsStart 2015-12

  National Institute of Mental Health (NIMH)United StatesNCT02543983

• KetamineRecruiting
  Ketamine Alcohol (in Treatment-Resistant Depression)

  Phase 2Magnetic Resonance Imaging, Major Depression, Alcoholism60 participantsStart 2014-04

  Mark NiciuUnited StatesNCT02122562

• PsilocybinSuspended
  Safety Profile of Psilocybin for Cocaine Use Disorder

  Early phase 1Cocaine Use Disorder10 participantsStart 2029-02

  University of California, Los AngelesUnited StatesNCT06102434

• PsilocybinWithdrawn
  Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

  Phase 2Opioid Use DisorderStart 2027-04

  Johns Hopkins UniversityUnited StatesNCT06005662

• KetamineEnrolling by invitation
  Intramuscular Ketamine for Suicidal Patients in the Evanston Hospital Emergency Department for Suicidal Distress

  Suicidal, Suicidal Ideation, Suicidal Ideation and Behavior8 participantsStart 2026-09

  Endeavor HealthUnited StatesNCT07810023

• KetamineSuspended
  Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP)

  Early phase 1Posttraumatic Stress Disorder5 participantsStart 2026-09

  University of Wisconsin, MadisonUnited StatesNCT06378528

• PsilocybinActive, not recruiting
  Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies

  Phase 2Anxiety, Depression, Hematopoietic and Lymphatic System Neoplasm18 participantsStart 2026-05

  University of WashingtonUnited StatesNCT07336238

• PsilocybinWithdrawn
  Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies

  Phase 2Suicidal IdeationStart 2026-05

  University of New MexicoNCT07484906

• EsketamineActive, not recruiting
  The Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression

  Phase 4Depressed, Bariatric Surgery40 participantsStart 2026-05

  The First Hospital of Jilin UniversityChinaNCT07179913

• MDMAActive, not recruiting
  Study of Midomafetamine in Healthy Adults

  Phase 1Healthy Volunteers32 participantsStart 2026-04

  Resilient PharmaceuticalsUnited StatesNCT07584720

• KetamineActive, not recruiting
  A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression

  Phase 2Major Depressive Disorder (MDD)12 participantsStart 2026-03

  Daniel LindqvistSwedenNCT07396272

• MDMAWithdrawn
  A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders

  Phase 2Anorexia Nervosa Restricting Type, Binge-Eating DisorderStart 2026-02

  Resilient PharmaceuticalsNCT04454684

• EsketamineEnrolling by invitation
  Psychotherapy Combined With Intranasal Esketamine for the Treatment of Suicidal Ideation

  Suicidal Ideation56 participantsStart 2026-01

  University of California, San DiegoUnited StatesNCT07396220

• KetamineWithdrawn
  The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series

  Phase 2 / Phase 3Postpartum DepressionStart 2025-10

  Washington University School of MedicineUnited StatesNCT06048263

• DMT5-MeO-DMTIbogaineWithdrawn
  Trifecta Research Study

  Phase 2PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain TraumaStart 2025-09

  Johns Hopkins UniversityUnited StatesNCT06810765

• MDMACompleted
  Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants

  Phase 1Healthy26 participantsStart 2025-07

  University Hospital, Basel, SwitzerlandSwitzerlandNCT06905652

• PsilocybinCompleted
  A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers

  Phase 1Healthy Volunteer20 participantsStart 2025-07

  MycoMedica Life Sciences PBCUnited KingdomNCT07050368

• KetamineTerminated
  A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients

  Phase 2Depression1 participantsStart 2025-07

  Mayo ClinicUnited StatesNCT05803551

• MDMAWithdrawn
  MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents

  Phase 2PTSD, Post Traumatic Stress Disorder, Adolescents, PsychotherapyStart 2025-07

  University of California, Los AngelesUnited StatesNCT06353282

• KetamineCompleted
  Electroconvulsive Therapy Versus Intravenous Ketamine in Treatment-Resistant Major Depressive Disorder

  Electroconvulsive Therapy, Intravenous Ketamine, Treatment-Resistant70 participantsStart 2025-07

  Tanta UniversityEgyptNCT07526454

• KetamineCompleted
  Ketamine Administration for Postoperative Pain Management in Patients Undergoing Knee Arthroplasty

  Knee Arthroplasty, Postoperative Pain, Pain Management100 participantsStart 2025-07

  State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of RussiaRussiaNCT07059429

• KetamineCompleted
  Reducing Pain With Methadone and Ketamine in Liver Transplant

  Phase 4Liver Transplantation50 participantsStart 2025-06

  Lahey ClinicUnited StatesNCT06868589

• LSDCompleted
  Drug Effects on Mood and Behavior - Expectancy

  Early phase 1LSD42 participantsStart 2025-06

  University of ChicagoUnited StatesNCT07061886

• LSDCompleted
  Mood Effects of Serotonin Agonists: Depression

  Early phase 1LSD, Major Depressive Disorder, Depression41 participantsStart 2025-06

  University of ChicagoUnited StatesNCT07017478

• EsketamineCompleted
  A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression

  Phase 4Depressive Disorder, Treatment-Resistant47 participantsStart 2025-06

  Janssen Korea, Ltd., KoreaSouth KoreaNCT07053345

• EsketamineCompleted
  Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)

  Phase 1 / Phase 2Post Traumatic Stress Disorder PTSD4 participantsStart 2025-06

  The University of Texas Health Science Center at San AntonioUnited StatesNCT06795659

• KetamineEnrolling by invitation
  Ketamine Effects on Learning In Eating Disorders

  Phase 2Anorexia Nervosa, Atypical Anorexia Nervosa20 participantsStart 2025-06

  Amanda Downey, MDUnited StatesNCT06736769

• PsilocybinActive, not recruiting
  PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)

  Phase 2Alcohol Use Disorder (AUD), PTSD40 participantsStart 2025-06

  Nathan Brashares SackettUnited StatesNCT06853912

• PsilocybinEnrolling by invitation
  Psilocybin With Intracranial Neural Sensing

  Phase 1Chronic Pain20 participantsStart 2025-06

  Joshua Woolley, MD, PhDUnited StatesNCT06919640

• MDMAEnrolling by invitation
  High-Intensity Inpatient MDMA-Assisted Psychotherapy for PTSD

  Phase 2Posttraumatic Stress Disorder (PTSD)20 participantsStart 2025-05

  ARQ National Psychotrauma CentreNetherlandsNCT06954025

• KetamineWithdrawn
  Repeated Neurocognitive Measurements in Depressed Patients

  Phase 1 / Phase 2Depression, UnipolarStart 2025-05

  Jay FournierUnited StatesNCT05991232

• PsilocybinCompleted
  Psilocybin Brain Stimulation and Imaging Pilot Study

  Phase 1Healthy Volunteers10 participantsStart 2025-04

  Johns Hopkins UniversityUnited StatesNCT06835699

• PsilocybinMDMACompleted
  Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects

  Phase 1Healthy24 participantsStart 2025-04

  University Hospital, Basel, SwitzerlandSwitzerlandNCT06884514

• KetamineSuspended
  Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery

  Phase 1Pain, Postpartum Depression50 participantsStart 2025-03

  University of UtahUnited StatesNCT06767566

• PsilocybinActive, not recruiting
  Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study

  Phase 2Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe16 participantsStart 2025-03

  McMaster UniversityCanadaNCT06225232

• PsilocybinActive, not recruiting
  Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism

  Alcohol Use Disorder20 participantsStart 2025-03

  Healing Advocacy FundUnited StatesNCT07189988

• KetamineCompleted
  Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV

  Phase 2Methamphetamine Use Disorder17 participantsStart 2025-03

  Nicky Mehtani, MD, MPHUnited StatesNCT06538285

• KetamineActive, not recruiting
  Propofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression

  Phase 4Chronic Pain, Depression40 participantsStart 2025-01

  Stanford UniversityUnited StatesNCT06317636

• PsilocybinUnknown
  Psychedelic-assisted Group Program for First Responders

  Phase 1 / Phase 2Psilocybin, Psychotherapy, Group32 participantsStart 2025-01

  Empower Research IncCanadaNCT06471959

• PsilocybinWithdrawn
  Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder

  Phase 1Post-Traumatic Stress DisorderStart 2025-01

  Johns Hopkins UniversityNCT05562973

• PsilocybinCompleted
  Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures

  Psychogenic Nonepileptic Seizures, Psilocybin4 participantsStart 2024-12

  Centre Hospitalier Universitaire de NīmesFranceNCT06647056

• PsilocybinCompleted
  Safety for Home Administration of Microdose Psilocybin Use

  Phase 1Psychedelic Experiences17 participantsStart 2024-12

  Johns Hopkins UniversityUnited StatesNCT06450210

• PsilocybinCompleted
  Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers

  Phase 2Major Depressive Disorder60 participantsStart 2024-12

  Khyber Medical University PeshawarPakistanNCT06746441

• MDMAWithdrawn
  Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers (MT-2)

  Phase 1Psychological Effects of Study DrugStart 2024-12

  Resilient PharmaceuticalsNCT04073433

• PsilocybinCompleted
  Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression

  Depressive Disorder, Depressive Disorder, Treatment-Resistant, Hallucinogens10 participantsStart 2024-11

  Centre Hospitalier Universitaire de NīmesFranceNCT06650800

• PsilocybinCompleted
  A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer

  Phase 1Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm15 participantsStart 2024-11

  University of WashingtonUnited StatesNCT06644170

• KetamineCompleted
  FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression

  Phase 2Bipolar Depression, Treatment Resistant Bipolar Depression20 participantsStart 2024-11

  Brian BarnettUnited StatesNCT06620042

• PsilocybinCompleted
  A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants

  Phase 1Healthy Volunteers16 participantsStart 2024-11

  MycoMedica Life Sciences PBCAustraliaNCT06643637

• PsilocybinActive, not recruiting
  Psilocybin for Treatment-Resistant Depression in Autism

  Phase 1Treatment Resistant Depression, Autism Spectrum Disorder20 participantsStart 2024-11

  Centre for Addiction and Mental HealthCanadaNCT06731621

• KetamineActive, not recruiting
  Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment

  Phase 2Depression, Mild Cognitive Impairment15 participantsStart 2024-11

  Icahn School of Medicine at Mount SinaiUnited StatesNCT06069843

• PsilocybinUnknown
  The Effects of Psilocybin on Shared Experience in Film Processing

  Disorders of Consciousness, Psychedelic Experiences30 participantsStart 2024-11

  Western University, CanadaNCT06529939

• MDMAActive, not recruiting
  MDMA-assisted Massed Prolonged Exposure for PTSD

  Phase 3Post-Traumatic Stress Disorder20 participantsStart 2024-10

  Healing BreakthroughUnited StatesNCT06117306

• KetamineCompleted
  Superficial Cervical Plexus Block Versus Ketamine in the Prevention of Chronic Pain After Thyroidectomy

  Phase 4Chronic Pain, Thyroidectomy69 participantsStart 2024-10

  University Tunis El ManarTunisiaNCT07230392

• PsilocybinActive, not recruiting
  Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression

  Phase 1Bipolar Depression30 participantsStart 2024-10

  University Health Network, TorontoCanadaNCT06506019

• EsketamineCompleted
  Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer

  Ovarian Cancer, Cytoreductive Surgery, Depressive Symptom568 participantsStart 2024-10

  Zhejiang Cancer HospitalChinaNCT06624878

• PsilocybinWithdrawn
  Optimizing Microdosing and Meditation

  Meditation, MicrodosingStart 2024-10

  National University of Natural MedicineUnited StatesNCT06560658

• EsketamineCompleted
  Effect of Esketamine on Perioperative Negative Mood in Patients Undergoing Cardiac Valve Surgery

  Depression, Anxiety, Cardiac Surgery, S-ketamine142 participantsStart 2024-09

  Chinese PLA General HospitalChinaNCT06608030

• KetamineActive, not recruiting
  Ketamine for Methamphetamine Use Disorder

  Phase 2Substance Use Disorders, Substance Use, Methamphetamine Abuse120 participantsStart 2024-09

  University of Texas Southwestern Medical CenterUnited StatesNCT06496750

• PsilocybinCompleted
  Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD

  Phase 1Obsessive-Compulsive Disorder10 participantsStart 2024-09

  Centre for Addiction and Mental HealthCanadaNCT06299319

• PsilocybinUnknown
  Psilocybin-assisted Therapy for Alcohol Use Disorder

  Phase 2Alcohol Use Disorder, Alcohol Dependence, Depression90 participantsStart 2024-09

  University of SydneyNCT06444243

• MDMAActive, not recruiting
  MDMA-Assisted Therapy for Pathological Narcissism

  Early phase 1Narcissism12 participantsStart 2024-08

  University of WashingtonUnited StatesNCT06565494

• EsketamineUnknown
  Electroencephalographic Characteristics of Chronic Pain in Patients With Spinal Cord Injury

  Chronic Pain60 participantsStart 2024-08

  Beijing Tiantan HospitalChinaNCT06531837

• LSDCompleted
  Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy

  Depression, Anxiety10 participantsStart 2024-08

  Tatiana Aboulafia BrakhaSwitzerlandNCT06557239

• PsilocybinCompleted
  Low-Income Group Psilocybin Assisted Therapy for Depression

  Depression20 participantsStart 2024-08

  Matthew HicksUnited StatesNCT06372197

• DMTUnknown
  Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects

  Phase 1Healthy Volunteers52 participantsStart 2024-08

  GH Research Ireland LimitedUnited KingdomNCT06511947

• PsilocybinCompleted
  Psilocybin for Treatment-Resistant Depression

  Phase 2Major Depressive Disorder, Anhedonia, Treatment Resistant Depression20 participantsStart 2024-07

  University of Colorado, DenverUnited StatesNCT06230757

• IbogaineCompleted
  Multiple Ascending Dose Noribogaine PK/PD in Healthy Volunteers

  Phase 1Pharmacokinetics55 participantsStart 2024-06

  DemeRx NBUnited KingdomNCT06480981

• EsketamineCompleted
  (GluEsk) Glutamate and Esketamine

  Depression16 participantsStart 2024-06

  University of OxfordUnited KingdomNCT06432322

• KetamineTerminated
  Ketamine for OUD and Suicidal Ideation in the ED

  Phase 2Opioid Use Disorder, Suicidal Ideation4 participantsStart 2024-06

  Brigham and Women's HospitalUnited StatesNCT06111339

• DMTCompleted
  Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study)

  Phase 1Healthy36 participantsStart 2024-06

  University Hospital, Basel, SwitzerlandSwitzerlandNCT05695495

• EsketamineTerminated
  Behavioural Activation Therapy and Esketamine for Resistant Depression

  Depressive Disorder, Treatment-Resistant, Depressive Disorder, Major, Bipolar Disorder6 participantsStart 2024-06

  The Royal's Institute of Mental Health ResearchCanadaNCT06431386

• PsilocybinActive, not recruiting
  A Study of Psilocybin for PTSD

  Phase 1Post Traumatic Stress Disorder20 participantsStart 2024-06

  Johns Hopkins UniversityUnited StatesNCT06407635

• PsilocybinActive, not recruiting
  Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer

  Phase 2Advanced Cancer, Stage IV Solid Tumor Cancer, Stage IV Sarcoma of Bone15 participantsStart 2024-06

  University Health Network, TorontoCanadaNCT06416085

• KetamineUnknown
  Dose Low Dose Ketamine in Casesarian

  Postoperative Pain, Postpartum Depression150 participantsStart 2024-06

  Inonu UniversityTurkey (Türkiye)NCT06237569

• MDMAWithdrawn
  The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.

  Phase 1Post Traumatic Stress DisorderStart 2024-05

  Yale UniversityUnited StatesNCT03752918

• PsilocybinActive, not recruiting
  Psilocybin-Assisted Therapy in Treatment-Resistant Depression

  Phase 3Refractory Depression, Treatment Resistant Depression20 participantsStart 2024-04

  University of North Carolina, Chapel HillUnited StatesNCT06303739

• EsketamineCompleted
  Esketamine vs ECT for Acute Suicidality

  Mood Disorders, Suicidal Ideation, Depressive Episode340 participantsStart 2024-04

  Capital Medical UniversityChinaNCT06355180

• PsilocybinCompleted
  A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants

  Phase 1Healthy Volunteers24 participantsStart 2024-03

  MycoMedica Life Sciences PBCAustraliaNCT06326606

• KetamineCompleted
  Opioid-based Versus Opioid-free Endotracheal Intubation

  Anesthesia, Anesthesia Intubation, Opioid Use70 participantsStart 2024-03

  Aretaieion University HospitalGreeceNCT06464393

• PsilocybinActive, not recruiting
  Psilocybin for Major Depressive Disorder (MDD)

  Phase 3Depressive Disorder, Major238 participantsStart 2024-03

  Usona InstituteUnited StatesNCT06308653

• LSDCompleted
  LSD-Perceptual-Choice-Study

  LSD Reaction30 participantsStart 2024-02

  University Hospital, Basel, SwitzerlandSwitzerlandNCT05976698

• PsilocybinUnknown
  Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder

  Phase 2Severe Alcohol Use Disorder62 participantsStart 2024-02

  Brugmann University HospitalBelgiumNCT06160232

• PsilocybinCompleted
  Psilocybin in Functional Neurological Disorder

  Functional Neurological Disorder20 participantsStart 2024-02

  King's College LondonUnited KingdomNCT05723276

• MDMAEnrolling by invitation
  MDMA Plus Exposure Therapy for PTSD

  Phase 2PTSD40 participantsStart 2024-02

  Emory UniversityUnited StatesNCT05746572

• MDMACompleted
  MDMA for AUD/PTSD Comorbidity

  Phase 2Alcohol Use Disorder, Post Traumatic Stress Disorder22 participantsStart 2024-02

  Carolina L Haass-KofflerUnited StatesNCT05943665

• PsilocybinActive, not recruiting
  Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin

  Phase 2Major Depressive Disorder, Depression, Treatment-Resistant Depression92 participantsStart 2024-02

  University Health Network, TorontoCanadaNCT06341426

• PsilocybinCompleted
  Psilocybin in Alcohol Use Disorder With Comorbid Depression

  Alcohol-Related Disorders, Depressive Disorder, Addiction30 participantsStart 2024-02

  Centre Hospitalier Universitaire de NīmesFranceNCT06235411

• PsilocybinKetamineActive, not recruiting
  Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder

  Phase 2Alcohol Use Disorder20 participantsStart 2024-02

  Peggy C NopoulosUnited StatesNCT05421065

• LSDCompleted
  Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects

  Phase 1Healthy20 participantsStart 2024-02

  University Hospital, Basel, SwitzerlandSwitzerlandNCT05964647

• DMTCompleted
  Molecular Imaging Study of Harmine/DMT: a Basic Research Approach

  Phase 1Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine17 participantsStart 2024-01

  Insel Gruppe AG, University Hospital BernSwitzerlandNCT06252506

• KetamineActive, not recruiting
  Predictors of Intravenous Ketamine Response in TRD

  Phase 3Treatment Resistant Depression, Major Depressive Disorder, Bipolar Disorder40 participantsStart 2024-01

  Abraham NunesCanadaNCT05625555

• KetamineUnknown
  Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation

  Suicidal Ideation, Suicidal Ideas20 participantsStart 2024-01

  Children's Hospital of Eastern OntarioCanadaNCT06366334

• PsilocybinActive, not recruiting
  PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL)

  Phase 1 / Phase 2Depression, Anxiety, Distress, Emotional20 participantsStart 2024-01

  Ottawa Hospital Research InstituteCanadaNCT04754061

• PsilocybinWithdrawn
  Psilocybin for Major Depressive Disorder

  Phase 2Major Depressive DisorderStart 2024-01

  Washington University School of MedicineNCT05675800

• EsketamineUnknown
  Effect of Esketamine on Depressive Symptoms of Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy

  Depressive Symptoms400 participantsStart 2024-01

  The Second Hospital of Anhui Medical UniversityNCT06199011

• KetamineWithdrawn
  Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD

  Phase 1 / Phase 2PTSDStart 2023-12

  University of New MexicoUnited StatesNCT06036511

• PsilocybinActive, not recruiting
  Psilocybin Therapy for Chronic Low Back Pain

  Phase 1 / Phase 2Chronic Low-back Pain30 participantsStart 2023-12

  Joshua Woolley, MD, PhDUnited StatesNCT05351541

• PsilocybinWithdrawn
  Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use

  Phase 2Opioid Use DisorderStart 2023-12

  Johns Hopkins UniversityNCT05242029

• PsilocybinActive, not recruiting
  Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment

  Phase 2Amnestic Mild Cognitive Impairment10 participantsStart 2023-11

  Centre for Addiction and Mental HealthCanadaNCT06041152

• MDMACompleted
  Acute Effects of 3,4-methylenedioxymethamphetamine (MDMA) With and Without a Booster Dose

  Phase 1Healthy25 participantsStart 2023-11

  University Hospital, Basel, SwitzerlandSwitzerlandNCT05809271

• LSDActive, not recruiting
  LSD Occupancy of the Serotonin 2A Receptor in the Human Brain

  Early phase 1Basic Science40 participantsStart 2023-11

  Rigshospitalet, DenmarkDenmarkNCT05953038

• PsilocybinCompleted
  Consciousness, Psilocybin, and Well-Being

  Phase 1Healthy, Psychedelic Experiences, Sleep6 participantsStart 2023-11

  University of Wisconsin, MadisonUnited StatesNCT05592379

• PsilocybinCompleted
  Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

  Phase 2Borderline Personality Disorder, Major Depressive Disorder9 participantsStart 2023-11

  University of ChicagoUnited StatesNCT05399498

• KetamineWithdrawn
  Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional Distress

  Early phase 1Cancer-related Problem/Condition, Depressive Symptoms, Anxiety DisordersStart 2023-10

  Northwell HealthNCT05344625

• KetamineCompleted
  Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion

  Phase 4Depression, Anxiety110 participantsStart 2023-10

  Benha UniversityEgyptNCT06060210

• EsketamineWithdrawn
  VA Aripiprazole vs Esketamine for Treatment Resistant Depression

  Phase 4Depressive Disorder, MajorStart 2023-10

  VA Office of Research and DevelopmentUnited StatesNCT05554627

• PsilocybinMDMACompleted
  Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans

  Phase 1Healthy122 participantsStart 2023-10

  University of ZurichSwitzerlandNCT06081179

• PsilocybinActive, not recruiting
  Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer

  Phase 2Cancer, Major Depressive Disorder56 participantsStart 2023-10

  Sunstone MedicalUnited StatesNCT05947383

• KetamineTerminated
  Ketamine-assisted Psychotherapy (KAP) for Patients With Existential Distress Associated With Non-operable GI Cancers

  Early phase 1Gastrointestinal Cancer, Depression, Anxiety2 participantsStart 2023-10

  University of UtahUnited StatesNCT06001372

• KetamineCompleted
  Psychotherapy for Ketamine's Enhanced Durability in Chronic Neuropathic Pain: A Randomized Controlled Pilot Trial

  Phase 4Neuropathic Pain30 participantsStart 2023-10

  Unity Health TorontoCanadaNCT05639322

• EsketamineUnknown
  Effect of Esketamine on Reducing Postoperative Anxiety and Depression in Adolescent Patients

  Early phase 1Anxiety-depression200 participantsStart 2023-10

  Henan Provincial People's HospitalNCT06073015

• DMTCompleted
  Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression

  Phase 2Depressive Disorder, Depression, Unipolar14 participantsStart 2023-10

  Universidade Federal do Rio Grande do NorteBrazilNCT06094907

• MDMACompleted
  MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD

  Phase 3PTSD, Relational Problems16 participantsStart 2023-10

  Dr. Leslie MorlandUnited StatesNCT05979844

• KetamineCompleted
  KET-RO Plus RO DBT for Treatment Resistant Depression

  Phase 1Treatment Resistant Depression16 participantsStart 2023-10

  Washington University School of MedicineUnited StatesNCT06138691

• MDMACompleted
  Group MDMA-therapy for Veterans With PTSD

  Phase 1 / Phase 2PTSD23 participantsStart 2023-10

  Portland VA Research Foundation, IncUnited StatesNCT05961527

• KetamineEnrolling by invitation
  Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan

  Phase 4Acute Suicidal Depression (ASD)1500 participantsStart 2023-10

  Brigham and Women's HospitalCanada + 1 moreNCT06034821

• PsilocybinCompleted
  Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia

  Phase 2Fibromyalgia17 participantsStart 2023-09

  Kevin BoehnkeUnited StatesNCT05128162

• KetamineCompleted
  Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery (PREPARE 1)

  Phase 1Pain, Postoperative, Depression, Postpartum12 participantsStart 2023-09

  Grace Lim, MD, MSUnited StatesNCT05907213

• MDMAUnknown
  MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder

  Phase 2PTSD, Alcohol Use Disorder, Alcohol Dependence120 participantsStart 2023-09

  University of SydneyAustraliaNCT05709353

• EsketamineActive, not recruiting
  Effect of Low-dose Esketamine on Maternal Depression at 3 Years After Childbirth

  Phase 4Prenatal Depression, Ketamine, Postpartum Depression364 participantsStart 2023-09

  Peking University First HospitalChinaNCT05698394

• PsilocybinUnknown
  A Community of Practice Program With Psilocybin-assisted Therapy for End-of-Life Patients

  Early phase 1End of Life64 participantsStart 2023-09

  The Roots to Thrive Society for Psychedelic TherapyNCT05958758

• PsilocybinCompleted
  Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder

  Phase 2Alcohol Use Disorder60 participantsStart 2023-09

  Anders Fink-Jensen, MD, DMSciDenmarkNCT05416229

• KetamineWithdrawn
  Ketamine for the Treatment for Alcohol Use Disorder in the ED

  Phase 2Alcohol Use DisorderStart 2023-09

  Brigham and Women's HospitalUnited StatesNCT05661669

• MDMAWithdrawn
  Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans

  Phase 2PTSDStart 2023-09

  Resilient PharmaceuticalsNCT05173831

• KetamineWithdrawn
  Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.

  Neuropathic PainStart 2023-09

  Assistance Publique - Hôpitaux de ParisNCT05949554

• KetamineCompleted
  Adding Ketamine to Levobupivacaine in Paravertebral Block in Thoracotomy

  Phase 4Ketamine, Levobupivacaine, Paravertebral Block60 participantsStart 2023-08

  Tanta UniversityEgyptNCT06011746

• KetamineActive, not recruiting
  Enhancing Week-long Psychological Treatment for PTSD With Ketamine

  Phase 2Posttraumatic Stress Disorder350 participantsStart 2023-08

  Yale UniversityIsrael, United StatesNCT05737693

• PsilocybinMDMA2C-BCompleted
  Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects

  Phase 1Healthy24 participantsStart 2023-08

  University Hospital, Basel, SwitzerlandSwitzerlandNCT05523401

• PsilocybinWithdrawn
  Exploratory Study of Low Dose Psilocybin

  Early phase 1DemoralizationStart 2023-08

  University of Alabama at BirminghamUnited StatesNCT05227742

• PsilocybinActive, not recruiting
  Neural and Physiological Correlates of Psychedelic Sub-states

  Phase 1Psychedelic Experiences, Neuroimaging, Healthy Volunteers12 participantsStart 2023-07

  Robin Carhart-Harris, PhD, MAUnited StatesNCT05698511

• MDMACompleted
  Prosocial Effects of MDMA

  Early phase 1MDMA ('Ecstasy'), Social Interaction33 participantsStart 2023-07

  University of ChicagoUnited StatesNCT05948683

• PsilocybinActive, not recruiting
  Effects of Repeated Psilocybin Dosing in OCD

  Phase 1Obsessive-Compulsive Disorder28 participantsStart 2023-07

  Yale UniversityUnited StatesNCT05370911

• PsilocybinCompleted
  Microdosing Psychedelics to Improve Mood

  Phase 2Major Depressive Disorder39 participantsStart 2023-07

  Rotem PetrankerCanadaNCT05259943

• MescalineUnknown
  Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis

  Phase 4Lupus Nephritis205 participantsStart 2023-07

  Xiangya Hospital of Central South UniversityNCT05933213

• KetamineUnknown
  Reversal of Battle-Related Aging (ROBRA) in a Special Operations Forces Cohort

  Post-Traumatic Stress Disorder, Traumatic Brain Injury20 participantsStart 2023-07

  Stella CenterUnited StatesNCT05855876

• EsketamineCompleted
  Brain Network Dynamics of Depression During Esketamine Treatment

  Depressive Disorder, Major8 participantsStart 2023-07

  University of North Carolina, Chapel HillUnited StatesNCT06012916

• PsilocybinCompleted
  Does Psilocybin Require Psychedelic Effects to Treat Depression?

  Phase 2Treatment-resistant Depression41 participantsStart 2023-07

  Centre for Addiction and Mental HealthCanadaNCT05710237

• PsilocybinWithdrawn
  PET Synaptogenesis After Psilocybin In DEpression Recovery

  Phase 2Major Depressive Disorder, AnhedoniaStart 2023-07

  Washington University School of MedicineUnited StatesNCT05601648

• PsilocybinCompleted
  Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer

  Phase 1 / Phase 2Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm55 participantsStart 2023-06

  University of WashingtonUnited StatesNCT05847686

• PsilocybinCompleted
  Psilocybin-assisted CBT for Depression

  Phase 1Major Depressive Disorder16 participantsStart 2023-06

  University of California, Los AngelesUnited StatesNCT05227612

• PsilocybinUnknown
  Evaluation of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans

  Phase 2PTSD8 participantsStart 2023-06

  Combat StressUnited KingdomNCT05876481

• PsilocybinWithdrawn
  Bioavailability Study of Psilocybin in Normal Adults

  Phase 1HealthyStart 2023-06

  University of Wisconsin, MadisonUnited StatesNCT05467761

• KetamineUnknown
  Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation

  Phase 3Suicidal Ideation20 participantsStart 2023-06

  University of OttawaCanadaNCT05468840

• 5-MeO-DMTCompleted
  A Trial of GH001 in Patients With Treatment-resistant Depression

  Phase 2Treatment-resistant Depression81 participantsStart 2023-05

  GH Research Ireland LimitedCzechia, Germany, Ireland + 3 moreNCT05800860

• KetamineCompleted
  Lidocaine and Ketamine Levels in Plasma After Simultaneous Lidocaine/Ketamine Infusions

  Chronic Pain15 participantsStart 2023-05

  University Hospital, Basel, SwitzerlandSwitzerlandNCT05906121

• DMTCompleted
  Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects

  Phase 1Healthy16 participantsStart 2023-05

  Reconnect LabsSwitzerlandNCT05829603

• EsketamineUnknown
  Effects of Epidural Labor Analgesia With Esketamine on the Incidence of Postpartum Depression in Parturients

  Phase 4Postpartum Depression364 participantsStart 2023-05

  Women's Hospital School Of Medicine Zhejiang UniversityChinaNCT05826327

• DMTCompleted
  Safety and Tolerability of DMT in Healthy Adults

  Phase 1Safety Issues, Healthy Volunteers25 participantsStart 2023-04

  Universidade Federal do Rio Grande do NorteBrazilNCT05901012

• KetamineTerminated
  Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy

  Phase 2 / Phase 3Pain Management, Opioid Use, Prostate Cancer58 participantsStart 2023-04

  Wake Forest University Health SciencesUnited StatesNCT05597878

• PsilocybinCompleted
  Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers

  Phase 1Pancreas Cancer, Biliary Tract Cancer, Psychological Distress18 participantsStart 2023-04

  University of NebraskaUnited StatesNCT05220046

• 5-MeO-DMTTerminated
  Phase 2 Clinical Trial of GH001 in Bipolar II Disorder

  Phase 2Bipolar II Disorder6 participantsStart 2023-04

  GH Research Ireland LimitedGermany, Netherlands, United KingdomNCT05839509

• PsilocybinSuspended
  An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome

  Phase 2Fragile X Syndrome, Behavior, Cognitive Dysfunction10 participantsStart 2023-03

  Nova Mentis Life Science CorpCanadaNCT05832255

• PsilocybinCompleted
  Psilocybin-assisted Interpersonal Therapy for Depression

  Depressive Disorder, Treatment-Resistant5 participantsStart 2023-03

  University of OtagoNew ZealandNCT05581797

• PsilocybinTerminated
  Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

  Phase 1Methamphetamine Use Disorder, Substance-Related Disorders, Chemically-Induced Disorders5 participantsStart 2023-03

  University of Wisconsin, MadisonUnited StatesNCT05322954

• 5-MeO-DMTTerminated
  Phase 2 Clinical Trial of GH001 in Postpartum Depression

  Phase 2Postpartum Depression, Postnatal Depression10 participantsStart 2023-03

  GH Research Ireland LimitedNetherlands, United KingdomNCT05804708

• DMTCompleted
  Mindfulness and Psychedelics

  Early phase 1Healthy Participants40 participantsStart 2023-02

  Milan ScheideggerSwitzerlandNCT05780216

• PsilocybinActive, not recruiting
  Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

  Phase 3Treatment Resistant Depression572 participantsStart 2023-02

  COMPASS PathwaysCanada + 11 moreNCT05711940

• PsilocybinUnknown
  Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study

  Phase 2Alcohol Use Disorder (AUD)10 participantsStart 2023-02

  Anders Fink-Jensen, MD, DMSciDenmarkNCT04718792

• PsilocybinActive, not recruiting
  A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

  Phase 2Major Depressive Disorder102 participantsStart 2023-01

  COMPASS PathwaysUnited StatesNCT05733546

• PsilocybinCompleted
  Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

  Phase 3Treatment Resistant Depression258 participantsStart 2023-01

  COMPASS PathwaysUnited StatesNCT05624268

• EsketamineWithdrawn
  Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study

  Phase 2Treatment Resistant Major Depressive DisorderStart 2023-01

  Zylorion HealthNCT05438758

• DMTActive, not recruiting
  Single and Repeat Doses of DMT in Healthy Subjects

  Phase 1Stroke60 participantsStart 2023-01

  Algernon PharmaceuticalsNetherlandsNCT05559931

• PsilocybinCompleted
  PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout

  Phase 1Depression, Burnout, Professional24 participantsStart 2023-01

  University of UtahUnited StatesNCT05557643

• PsilocybinWithdrawn
  Effect of SSRIs on Response to Psilocybin Therapy

  Phase 2Depression, Major Depressive Disorder, Mild DepressionStart 2023-01

  Cybin Therapeutics Inc.CanadaNCT05594667

• PsilocybinActive, not recruiting
  Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder

  Phase 2PTSD, Stress Disorders, Traumatic, Stress Disorders, Post-Traumatic15 participantsStart 2023-01

  Ohio State UniversityUnited StatesNCT05554094

• LSDUnknown
  The Effect of LSD on Neural Synchrony, Prosocial Behavior, and Relationship Quality

  Phase 1 / Phase 2Prosocial Behavior60 participantsStart 2023-01

  Maastricht UniversityNetherlandsNCT05670184

• KetamineWithdrawn
  Scheduled Intranasal Ketamine

  Early phase 1Pain, TraumaStart 2023-01

  Sanford HealthNCT05671913

• PsilocybinWithdrawn
  Mood and Cognitive Effects of Psilocybin in Healthy Participants

  Early phase 1Mood Disturbance, Mood Change, Sleep DisturbanceStart 2023-01

  Optimi Health CorporationNCT05252598

• KetamineUnknown
  An EEG Study of Intravenous Ketamine for Major Depression Disorder

  Phase 4Major Depressive Disorder35 participantsStart 2023-01

  Ehave Inc.NCT05506462

• DMTCompleted
  Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers

  Phase 1Pharmacokinetics, Safety, Tolerability54 participantsStart 2022-12

  Usona InstituteUnited StatesNCT05698095

• DMTCompleted
  Safety and Pharmacokinetics of GH002 in Healthy Volunteers

  Phase 1Healthy Volunteers64 participantsStart 2022-12

  GH Research Ireland LimitedNetherlandsNCT05753956

• DMTCompleted
  SPL026 With or Without SSRIs in Participants With MDD

  Phase 1Major Depressive Disorder18 participantsStart 2022-12

  Small Pharma LtdUnited KingdomNCT05553691

• PsilocybinCompleted
  Psilocybin in Adults With and Without Autism Spectrum Disorder

  Autism Spectrum Disorder67 participantsStart 2022-12

  King's College LondonUnited KingdomNCT05651126

• PsilocybinActive, not recruiting
  Effects of Psilocybin in Obsessive Compulsive Disorder

  Early phase 1Obsessive-Compulsive Disorder35 participantsStart 2022-11

  Johns Hopkins UniversityUnited StatesNCT05546658

• DMTCompleted
  Acute Dose-dependent Effects of DMT in Healthy Subjects

  Phase 1Healthy24 participantsStart 2022-11

  University Hospital, Basel, SwitzerlandSwitzerlandNCT05384678

• PsilocybinCompleted
  Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain

  Phase 1Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm11 participantsStart 2022-11

  Emory UniversityUnited StatesNCT05506982

• KetamineUnknown
  Opioid Sparing Anesthesia in Cervical Spine Surgery

  Pain, Postoperative, Pain, Acute, Pain, Chronic60 participantsStart 2022-11

  Evangelismos HospitalGreeceNCT05717361

• AyahuascaEsketamineCompleted
  Ayahuasca and Esketamine for Major Depression

  Phase 2Major Depression Severe22 participantsStart 2022-10

  University of Sao PauloBrazilNCT07212946

• IbogaineCompleted
  Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial

  Phase 2Alcoholism9 participantsStart 2022-10

  University of Sao PauloBrazilNCT03380728

• PsilocybinCompleted
  PsilOCD: A Pharmacological-Challenge Feasibility Study

  Phase 1Obsessive-Compulsive Disorder19 participantsStart 2022-10

  Imperial College LondonUnited KingdomNCT06258031

• PsilocybinMDMALSDEnrolling by invitation
  The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training

  Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD48 participantsStart 2022-10

  Felix MuellerSwitzerlandNCT05570708

• LSDCompleted
  Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects

  Phase 1Healthy24 participantsStart 2022-10

  University Hospital, Basel, SwitzerlandSwitzerlandNCT05175430

• KetamineCompleted
  Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer

  Early phase 1Anxiety, Pancreatic Cancer12 participantsStart 2022-10

  Cedars-Sinai Medical CenterUnited StatesNCT05086250

• EsketamineTerminated
  Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression

  Phase 2Treatment Resistant Major Depressive Disorder6 participantsStart 2022-10

  Zylorion HealthCanadaNCT05323019

• PsilocybinCompleted
  Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study

  Phase 2Anorexia Nervosa32 participantsStart 2022-10

  COMPASS PathwaysIreland, United Kingdom, United StatesNCT05481736

• PsilocybinUnknown
  Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder

  Phase 2Treatment Resistant Disorders, Post Traumatic Stress Disorder20 participantsStart 2022-10

  Halucenex Life Sciences Inc.CanadaNCT05243329

• PsilocybinCompleted
  Psilocybin-assisted Therapy for Phantom Limb Pain

  Phase 1Phantom Limb Pain10 participantsStart 2022-10

  University of California, San DiegoUnited StatesNCT05224336

• KetamineUnknown
  Auditory MMN EEG in TRD in Response to Ketamine

  Treatment-resistant Depression (TRD)30 participantsStart 2022-10

  Unity Health TorontoCanadaNCT05464264

• KetamineCompleted
  Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents

  Phase 3Suicide, Attempted, Suicide and Depression, Suicide Threat50 participantsStart 2022-10

  University of Texas Southwestern Medical CenterUnited StatesNCT04592809

• MDMACompleted
  Acute Effects of R- and S-MDMA in Healthy Subjects

  Phase 1Healthy24 participantsStart 2022-10

  University Hospital, Basel, SwitzerlandSwitzerlandNCT05277636

• PsilocybinWithdrawn
  The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD

  Phase 2Treatment-Resistant Major Depressive DisorderStart 2022-09

  Massachusetts General HospitalUnited StatesNCT05381974

• EsketamineWithdrawn
  A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression

  Phase 1DepressionStart 2022-09

  Janssen Research & Development, LLCUnited StatesNCT05268497

• KetamineWithdrawn
  Preoperative Ketamine and Perioperative Depression

  Phase 4Depressive DisorderStart 2022-09

  Northwestern UniversityNCT04220125

• LSDCompleted
  A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

  Phase 2Anxiety Generalized198 participantsStart 2022-08

  Definium Therapeutics US, Inc.United StatesNCT05407064

• PsilocybinUnknown
  Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action

  Fibromyalgia20 participantsStart 2022-08

  Imperial College LondonUnited KingdomNCT05548075

• KetamineCompleted
  Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression

  Phase 2Bipolar Disorder, Bipolar Depression, Bipolar I Disorder41 participantsStart 2022-08

  Joshua RosenblatCanadaNCT05339074

• DMTIbogaineActive, not recruiting
  Trifecta Research Study

  PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Injury52 participantsStart 2022-08

  Axial Therapeutic ResearchUnited StatesNCT07717866

• KetamineUnknown
  Opioid Sparing Anesthesia in Lumbar Spine Surgery

  Pain, Postoperative, Pain, Acute, Pain, Chronic60 participantsStart 2022-08

  Aretaieion University HospitalGreeceNCT05594407

• MDMAWithdrawn
  Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD

  Phase 2Posttraumatic Stress DisorderStart 2022-08

  Resilient PharmaceuticalsNCT04968938

• KetamineWithdrawn
  Opioid-Free Pain Control Regiment Following Robotic Radical Prostatectomy

  Phase 2 / Phase 3Radical ProstatectomiesStart 2022-08

  Wake Forest University Health SciencesUnited StatesNCT04939987

• MDMACompleted
  Food Effects on Bioavailability of MDMA in Healthy Volunteers

  Phase 1Pharmacokinetics14 participantsStart 2022-07

  Resilient PharmaceuticalsUnited StatesNCT05147402

• KetamineCompleted
  Anhedonia, Development, and Emotions: Phenotyping and Therapeutics

  Phase 4Depression, Anhedonia123 participantsStart 2022-07

  Erika ForbesUnited StatesNCT05487885

• PsilocybinActive, not recruiting
  Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder

  Phase 1 / Phase 2Amphetamine-Related Disorders30 participantsStart 2022-07

  Portland VA Research Foundation, IncUnited StatesNCT04982796

• KetamineCompleted
  Ketamine for Treatment-Resistant Bipolar Disorder

  Phase 2Bipolar Disorder, Bipolar Depression, Bipolar I Disorder71 participantsStart 2022-07

  Joshua RosenblatCanadaNCT05004896

• PsilocybinCompleted
  Effects of Psilocybin in Post-Treatment Lyme Disease

  Phase 1Post-Treatment Lyme Disease, Chronic Lyme Disease, Lyme Disease, Chronic20 participantsStart 2022-07

  Johns Hopkins UniversityUnited StatesNCT05305105

• KetamineUnknown
  Glutamate Emotion Memory Study

  Treatment Resistant Depression, Depression, Major Depressive Disorder60 participantsStart 2022-07

  University of OxfordUnited KingdomNCT05809609

• PsilocybinCompleted
  An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics

  Phase 1QTc Interval, Pharmacokinetics60 participantsStart 2022-06

  Usona InstituteUnited StatesNCT05478278

• PsilocybinCompleted
  The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

  Phase 2Post Traumatic Stress Disorder22 participantsStart 2022-06

  COMPASS PathwaysUnited Kingdom, United StatesNCT05312151

• DMTCompleted
  Clinical Study of DMT in Healthy Adults

  Phase 1Healthy Volunteers27 participantsStart 2022-06

  Biomind Labs Inc.BrazilNCT05573568

• KetamineEnrolling by invitation
  Observational Study of Ketamine Infusions for the Treatment of Chronic Pain

  Chronic Pain100 participantsStart 2022-06

  Theresa LiiUnited StatesNCT05477004

• KetamineTerminated
  Ketamine Infusion for Rapid Reduction of Suicidality in Pediatrics

  Phase 1 / Phase 2Suicidal Ideation15 participantsStart 2022-06

  University of British ColumbiaCanadaNCT04955470

• KetamineUnknown
  The Effect of Ketamine on Aesthetics and Role for Antidepressant Effects

  Phase 1Major Depressive Disorder60 participantsStart 2022-06

  Medical University of ViennaAustriaNCT05320107

• PsilocybinActive, not recruiting
  Comparing the Effects of Psilocin and Psilocybin in Healthy Adults

  Phase 1Healthy20 participantsStart 2022-05

  University of California, San FranciscoUnited StatesNCT05317689

• KetamineCompleted
  Infusion Treatments of Chronic Peripheral Neuropathic Pain

  Neuropathic Pain102 participantsStart 2022-05

  Hacettepe UniversityTurkey (Türkiye)NCT06297915

• KetamineCompleted
  Mechanism of Analgesic Effect on Prolonged Continuous Theta Burst Stimulation

  Chronic Pain, rTMS45 participantsStart 2022-05

  Second Affiliated Hospital, Zhejiang University, School of MedicineChinaNCT05360030

• MDMACompleted
  Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function

  Early phase 1Stimulant Use, MDMA ('Ecstasy'), Social Behavior43 participantsStart 2022-05

  University of ChicagoUnited StatesNCT05379959

• KetamineCompleted
  Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets

  Phase 2Major Depressive Disorder, Healthy Controls165 participantsStart 2022-05

  University of Texas Southwestern Medical CenterUnited StatesNCT05046184

• KetamineCompleted
  Neural Correlates of Ketamine's Anti-suicidal Effects in Bipolar Depression

  Bipolar Disorder (BD), Suicidality16 participantsStart 2022-05

  Centre for Addiction and Mental HealthCanadaNCT05177146

• PsilocybinUnknown
  Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)

  Phase 2Alcohol Use Disorder128 participantsStart 2022-05

  Clairvoyant TherapeuticsCanada + 1 moreNCT05646303

• LSDCompleted
  Effects of LSD on Neuroplasticity in Healthy Subjects

  Phase 1Healthy45 participantsStart 2022-05

  University of FribourgSwitzerlandNCT05177419

• KetamineCompleted
  Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial

  Phase 3Postoperative Depression32 participantsStart 2022-04

  Washington University School of MedicineUnited StatesNCT05233566

• MDMACompleted
  Social Anxiety MDMA-Assisted Therapy Investigation

  Phase 2Social Anxiety Disorder90 participantsStart 2022-04

  Jason B LuomaUnited StatesNCT05138068

• KetamineEnrolling by invitation
  Effect of Ketamine and Etomidate During RSI on Long Term Outcomes

  Post-Traumatic Stress Disorder, Acute Respiratory Failure1756 participantsStart 2022-04

  Vanderbilt University Medical CenterUnited StatesNCT06179485

• KetamineTerminated
  Ketamine for OUD and Comorbid Depression (OUDCD)

  Phase 1Opioid Use Disorder, Depressive Disorder5 participantsStart 2022-04

  University of Maryland, BaltimoreUnited StatesNCT05051449

• KetamineUnknown
  Ketamine and Epigenetic Aging

  Phase 2Depression, Post Traumatic Stress Disorder20 participantsStart 2022-04

  TruDiagnosticUnited StatesNCT05294835

• KetamineActive, not recruiting
  Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study

  Phase 4Major Depressive Disorder21 participantsStart 2022-03

  Ohio State UniversityUnited StatesNCT05950711

• PsilocybinCompleted
  The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

  Phase 2Treatment Resistant Depression, Suicidal Ideation20 participantsStart 2022-03

  Sheppard Pratt Health SystemUnited StatesNCT05220410

• LSDCompleted
  LSD Base and LSD Tartrate Bioequivalence and Bioavailability in Healthy Subjects

  Phase 1Healthy20 participantsStart 2022-03

  University Hospital, Basel, SwitzerlandSwitzerlandNCT04865653

• KetamineCompleted
  Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression

  Phase 4Treatment-resistant Depression, Major Depressive Disorder12 participantsStart 2022-03

  Taipei Veterans General Hospital, TaiwanTaiwanNCT05045378

• PsilocybinCompleted
  Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care

  Phase 2Hospice, Psilocybin, Demoralization15 participantsStart 2022-03

  Yvan Beaussant, MD, MSciUnited StatesNCT04950608

• KetamineUnknown
  Opioid-free Anesthesia in Thyroidectomies

  Pain, Post Operative, Pain, Acute, Pain, Chronic60 participantsStart 2022-03

  Aretaieion University HospitalGreeceNCT05243940

• PsilocybinCompleted
  Frontline Clinician Psilocybin Study

  Phase 3Burnout, Caregiver, Burnout, Professional, COVID-1930 participantsStart 2022-03

  University of WashingtonUnited StatesNCT05163496

• KetamineUnknown
  Low-Dose Intravenous Ketamine for Adolescents With Depression and Suicidal Ideation in the Emergency Department

  Early phase 1Depression, Suicidal Ideation30 participantsStart 2022-03

  Rady Children's Hospital, San DiegoUnited StatesNCT05217706

• EsketamineUnknown
  Effects of Esketamine on Postpartum Depression

  Phase 4Postpartum Depression500 participantsStart 2022-02

  Qinghai UniversityNCT05229913

• KetamineCompleted
  Ketamine + Mindfulness for Depression

  Phase 1 / Phase 2Depression, Unipolar43 participantsStart 2022-02

  Rebecca PriceUnited StatesNCT05168735

• KetamineWithdrawn
  Intramuscular Ketamine for Suicidal Ideation

  Phase 2Suicidal IdeationStart 2022-02

  Icahn School of Medicine at Mount SinaiUnited StatesNCT05105061

• PsilocybinActive, not recruiting
  Psilocybin Therapy for Depression in Bipolar II Disorder

  Phase 2Bipolar II Disorder14 participantsStart 2022-01

  University of California, San FranciscoUnited StatesNCT05065294

• KetamineTerminated
  Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine

  Phase 2Adolescent Suicide, Adolescent Depression12 participantsStart 2022-01

  Yale UniversityUnited StatesNCT04613453

• KetamineTerminated
  KAP for Depression in Abstinent Opioid Users

  Phase 2Opioid Use Disorder, Severe, in Sustained Remission, Opioid Use Disorder, Severe, in Early Remission, Major Depressive Disorder5 participantsStart 2022-01

  Medical University of South CarolinaUnited StatesNCT05193318

• LSDCompleted
  Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial

  Phase 2ADHD, Attention Deficit Disorder53 participantsStart 2021-12

  Definium Therapeutics US, Inc.Netherlands, SwitzerlandNCT05200936

• KetamineEnrolling by invitation
  Ketamine Infusion for Neuropathic Pain in Brachial Plexus Injuries

  Phase 4Brachial Plexus Injury100 participantsStart 2021-12

  Mayo ClinicUnited StatesNCT04933149

• MDMAUnknown
  Abuse Potential and Human Pharmacology of Methylone

  Phase 1Substance Use, Healthy Subjects17 participantsStart 2021-12

  Germans Trias i Pujol HospitalSpainNCT05488171

• MDMACompleted
  Effects of MDMA-like Substances in Healthy Subjects

  Phase 1Healthy23 participantsStart 2021-12

  University Hospital, Basel, SwitzerlandSwitzerlandNCT04847206

• EsketamineUnknown
  Intravenous Esketamine on Prevention of Postoperative Depression in Patients Undergoing Cardiac Surgery

  Postoperative Depression80 participantsStart 2021-12

  Anshi WuChinaNCT05155969

• KetamineCompleted
  Ketamine for the Treatment of Depression in Parkinson's Disease

  Phase 2Parkinson's Disease, Depression51 participantsStart 2021-11

  Yale UniversityUnited StatesNCT04944017

• PsilocybinCompleted
  Psilocybin for Treatment-Resistant Depression

  Phase 2Treatment Resistant Depression30 participantsStart 2021-11

  Brain and Cognition Discovery FoundationCanadaNCT05029466

• IbogaineActive, not recruiting
  Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure

  Blast or Combat Exposure, Head Injury Trauma30 participantsStart 2021-11

  Stanford UniversityUnited StatesNCT04313712

• MDMATerminated
  Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD

  Phase 2PTSD26 participantsStart 2021-11

  Resilient PharmaceuticalsUnited StatesNCT04784143

• KetamineCompleted
  Effectiveness of Ketamine Administered by Mesotherapy in Complex Regional Pain Syndrome Type 1 (CRPS1)

  Phase 2 / Phase 3Neuropathic Pain, Complex Regional Pain Syndrome Type 131 participantsStart 2021-11

  Hospices Civils de LyonFranceNCT04650074

• MDMACompleted
  Stanford Regulating Circuits of the Brain Study - MDMA

  Healthy22 participantsStart 2021-11

  Stanford UniversityUnited StatesNCT04060108

• KetamineCompleted
  Intranasal Ketamine in Ultra-REsistant Depression (SURE-ECT Non Responders)

  Depression25 participantsStart 2021-10

  Centre for Addiction and Mental HealthCanadaNCT05137938

• KetamineCompleted
  Synaptic Imaging and Network Activity in Treatment Resistant Depression

  Depressive Disorder, Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant56 participantsStart 2021-10

  King's College LondonUnited KingdomNCT05870501

• PsilocybinCompleted
  Identification of a Safe and Non-Psychedelic Dose of Psilocybin

  Phase 1Healthy Controls56 participantsStart 2021-10

  Diamond Therapeutics Inc.CanadaNCT07710027

• KetamineUnknown
  Opioid-free Anesthesia in Laparoscopic Cholecystectomies

  Pain, Postoperative, Pain, Acute, Pain, Chronic70 participantsStart 2021-10

  Aretaieion University HospitalGreeceNCT05089526

• EsketamineUnknown
  Effect of Esketamine on Postoperative Depression、Gut Microbiota、Bispectral Index Data of Depression Patients Undergoing Breast Cancer Operation (ESPOD-BI)

  Phase 4Depression72 participantsStart 2021-10

  China Medical University, ChinaChinaNCT04303325

• PsilocybinCompleted
  Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer

  Early phase 1Cancer12 participantsStart 2021-10

  University of UtahUnited StatesNCT04522804

• MDMACompleted
  A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)

  Phase 2Post Traumatic Stress Disorder10 participantsStart 2021-10

  RemedyCanadaNCT05067244

• KetamineCompleted
  Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine

  Early phase 1Depressive Disorder, Treatment-Resistant27 participantsStart 2021-09

  King's College LondonUnited KingdomNCT04977674

• DMT5-MeO-DMTCompleted
  Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects

  Phase 1Pharmacokinetics in Healthy Adults36 participantsStart 2021-09

  Beckley Psytech LimitedUnited KingdomNCT05032833

• KetamineCompleted
  Repeated Neurocognitive Measurements in Depressed Patients

  Phase 1 / Phase 2Depression, Unipolar15 participantsStart 2021-09

  Rebecca PriceUnited StatesNCT04916548

• KetamineCompleted
  Ketamine As an Adjunctive Therapy for Major Depression (2)

  Phase 3Major Depressive Episode, Unipolar Depression, Bipolar Depression63 participantsStart 2021-09

  University of Dublin, Trinity CollegeIrelandNCT04939649

• KetamineCompleted
  Effectiveness of Ketamine Treatment for Three Consecutive Days in Depression

  Phase 4Depression24 participantsStart 2021-09

  Mahidol UniversityThailandNCT05026203

• PsilocybinTerminated
  Visual Surround Suppression and Perceptual Expectation Under Psilocybin

  Phase 1Perception Disturbance, Visual Suppression, Psychedelic Experiences10 participantsStart 2021-08

  University of MinnesotaUnited StatesNCT04424225

• KetamineUnknown
  Reward Emotion Learning and Ketamine Study

  Depression, Major Depressive Disorder, Treatment Resistant Depression70 participantsStart 2021-08

  University of OxfordUnited KingdomNCT04850911

• PsilocybinCompleted
  Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease

  Phase 2Parkinson Disease, Depression, Anxiety12 participantsStart 2021-08

  Joshua Woolley, MD, PhDUnited StatesNCT04932434

• PsilocybinTerminated
  Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)

  Phase 1Short Lasting Unilateral Neuralgiform Headache Attacks4 participantsStart 2021-08

  Beckley Psytech LimitedUnited KingdomNCT04905121

• MescalineCompleted
  Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness

  Phase 1Healthy16 participantsStart 2021-08

  University Hospital, Basel, SwitzerlandSwitzerlandNCT04849013

• PsilocybinCompleted
  Repeat Dosing of Psilocybin in Migraine Headache

  Phase 1Migraine Headache18 participantsStart 2021-08

  Yale UniversityUnited StatesNCT04218539

• MDMACompleted
  Drug Effects on Interpersonal Interaction

  Early phase 1Interaction, Social30 participantsStart 2021-08

  University of ChicagoUnited StatesNCT05123716

• KetamineUnknown
  Combined Ketamine and eCBT Intervention for PTSD

  Phase 2Post-Traumatic Stress Disorder16 participantsStart 2021-08

  Queen's UniversityCanadaNCT04771767

• EsketamineUnknown
  The Effectiveness and Safety of Esketamine in Modified Electroconvulsive Therapy

  Early phase 1Esketamine, ECT, Depression396 participantsStart 2021-08

  First Affiliated Hospital of Chongqing Medical UniversityNCT04777110

• MDMACompleted
  MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD

  Phase 2Post Traumatic Stress Disorder, Combat Stress Disorders5 participantsStart 2021-07

  VA Loma Linda Health Care SystemUnited StatesNCT04264026

• EsketamineWithdrawn
  ECT vs. Esketamine

  Phase 3Treatment Resistant Depression, Major Depressive DisorderStart 2021-07

  Medical University InnsbruckAustriaNCT04924257

• EsketamineUnknown
  Comparison of Ketamine and Esketamine in Patients Suffering From Fibromyalgia Syndrome.

  Fibromyalgia50 participantsStart 2021-07

  Centre Hospitalier Universitaire de CharleroiBelgiumNCT04938713

• KetamineUnknown
  A Single Ketamine Infusion Combined With Music for Suicidal Ideation

  Phase 2Suicidal Ideation, Depressive Episode200 participantsStart 2021-07

  The University of Texas Health Science Center at TylerUnited StatesNCT04658420

• PsilocybinCompleted
  Psilocybin in Depression Resistant to Standard Treatments

  Phase 2Treatment Resistant Depression60 participantsStart 2021-06

  King's College LondonUnited KingdomNCT04959253

• DMTCompleted
  Pharmacokinetics of GH001 in Healthy Volunteers

  Phase 1Healthy Volunteers46 participantsStart 2021-06

  GH Research Ireland LimitedNetherlandsNCT05163691

• DMTCompleted
  Effects of Dimethyltryptamine in Healthy Subjects

  Phase 1Healthy31 participantsStart 2021-06

  University Hospital, Basel, SwitzerlandSwitzerlandNCT04353024

• PsilocybinCompleted
  Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression

  Phase 2Treatment-resistant Depression144 participantsStart 2021-06

  Central Institute of Mental Health, MannheimGermanyNCT04670081

• KetamineCompleted
  Adding Trauma-focused Psychotherapy to Ketamine Treatment for Chronic PTSD

  Phase 2PTSD16 participantsStart 2021-06

  Icahn School of Medicine at Mount SinaiUnited StatesNCT04889664

• PsilocybinCompleted
  Precision Functional Brain Mapping in Psilocybin

  Early phase 1Psilocybin11 participantsStart 2021-06

  Washington University School of MedicineUnited StatesNCT04501653

• PsilocybinCompleted
  Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study

  Phase 1 / Phase 2Anorexia Nervosa21 participantsStart 2021-05

  Imperial College LondonUnited KingdomNCT04505189

• PsilocybinCompleted
  Pilot RECAP Study in Healthy Volunteers

  Phase 1Psychedelic Experiences, Amnesia8 participantsStart 2021-05

  University of Wisconsin, MadisonUnited StatesNCT04842045

• PsilocybinCompleted
  Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy

  Phase 2Anorexia Nervosa16 participantsStart 2021-05

  University of California, San DiegoUnited StatesNCT04661514

• PsilocybinKetamineUnknown
  Psilocybin Versus Ketamine in Treatment-Resistant Depression

  Phase 2Treatment Resistant Depression60 participantsStart 2021-05

  National Institute of Mental Health, Czech RepublicCzechiaNCT05383313

• EsketamineCompleted
  Esketamine on Postpartum Depression in Cesarean Section Women

  Esketamine, Postpartum Depression336 participantsStart 2021-05

  Ailin LuoChinaNCT04860661

• EsketamineUnknown
  Esketamine Adjuvant Therapy for Patients With Chronic Visceral Pain Comorbid Major Depressive Disorder

  Chronic Visceral Pain, Major Depressive Disorder80 participantsStart 2021-05

  Peking UniversityNCT04847245

• KetamineUnknown
  Naturalistic Study of Ketamine in the Treatment of Depression

  Major Depressive Disorder, Bipolar Disorder, Bipolar Depression90 participantsStart 2021-05

  Hospital de Clinicas de Porto AlegreBrazilNCT05249309

• EsketamineUnknown
  Add-on Therapy With Edupression.Com® on Therapy Resistant Depressive Patients Treated With Nasal Esketamine Spray

  Major Depressive Disorder, Therapy Resistant Depression70 participantsStart 2021-04

  Lukas PezawasAustriaNCT04843462

• KetamineCompleted
  Ketamine Versus Fentanyl for Surgical Abortions

  Phase 4Abortion in First Trimester, Pain, Procedural, Opioid Use110 participantsStart 2021-04

  University of WashingtonUnited StatesNCT04871425

• EsketamineCompleted
  A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

  Phase 4Depressive Disorder, Major183 participantsStart 2021-04

  Janssen-Cilag Ltd.Argentina, Belgium, Bulgaria + 11 moreNCT04829318

• KetamineUnknown
  Morphine Versus Ketamine as Adjuvants in Paravertebral Blocks

  Pain, Postoperative, Pain, Acute, Pain, Chronic90 participantsStart 2021-04

  Aretaieion University HospitalGreeceNCT04852484

• PsilocybinActive, not recruiting
  Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

  Phase 2Major Depressive Disorder, Alcohol Use Disorder90 participantsStart 2021-04

  Johns Hopkins UniversityUnited StatesNCT04620759

• KetamineCompleted
  The Impact of Perioperative Ketamine Infusion on Surgical Recovery

  Phase 4Opioid Use, Enhanced Recovery After Surgery, Anesthesia1570 participantsStart 2021-04

  Vanderbilt University Medical CenterUnited StatesNCT04625283

• KetamineCompleted
  Modified Ketogenic Diet and Ketamine for Anorexia Nervosa

  Phase 1Anorexia Nervosa5 participantsStart 2021-04

  Homeostasis Therapeutics, LLCUnited StatesNCT04714541

• KetamineUnknown
  Opioid-free Anesthesia With a Mixture of Dexmedetomidine-lidocaine-ketamine

  Pain, Postoperative, Pain, Acute, Pain, Chronic60 participantsStart 2021-04

  Aretaieion University HospitalGreeceNCT04858711

• DMTActive, not recruiting
  Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans

  Phase 1Major Depressive Disorder, Depression30 participantsStart 2021-03

  Yale UniversityUnited StatesNCT04711915

• KetamineActive, not recruiting
  Ketamine + Cognitive Training for Suicidality in the Medical Setting

  Phase 4Suicide, Attempted200 participantsStart 2021-03

  Rebecca PriceUnited StatesNCT04578938

• KetamineCompleted
  Ketamine-enhanced Prolonged Exposure Therapy in PTSD

  Phase 2PTSD73 participantsStart 2021-03

  VA Office of Research and DevelopmentUnited StatesNCT04560660

• MDMACompleted
  A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD

  Phase 3PTSD87 participantsStart 2021-03

  Resilient PharmaceuticalsCanada + 2 moreNCT04714359

• PsilocybinUnknown
  The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

  Phase 2Treatment Resistant Depression15 participantsStart 2021-03

  Sheppard Pratt Health SystemUnited StatesNCT04433845

• PsilocybinUnknown
  An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

  Phase 2Treatment Resistant Depression27 participantsStart 2021-03

  Sheppard Pratt Health SystemUnited StatesNCT04433858

• PsilocybinCompleted
  Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder

  Phase 2Body Dysmorphic Disorders12 participantsStart 2021-02

  New York State Psychiatric InstituteUnited StatesNCT04656301

• EsketamineCompleted
  Esketamine and Perioperative Depressive Symptoms

  Phase 2 / Phase 3Depressive Symptoms, Esketamine, Perioperative Complication435 participantsStart 2021-02

  Beijing Tiantan HospitalChinaNCT04425473

• PsilocybinActive, not recruiting
  Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder

  Phase 2Alcohol Use Disorder20 participantsStart 2021-02

  Keith HeinzerlingUnited StatesNCT04410913

• EsketamineCompleted
  Effect of Low-dose Esketamine on Postoperative Depression in Patients With Breast Cancer

  Depression90 participantsStart 2021-02

  Yangzhou UniversityChinaNCT04850937

• KetamineSuspended
  IM Ketamine vs Midazolam for Suicidal ER Patients

  Phase 4Depression, Unipolar, Depression, Bipolar, Suicidal Ideation90 participantsStart 2021-02

  New York State Psychiatric InstituteUnited StatesNCT04640636

• MDMACompleted
  Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls

  Diabetes Insipidus30 participantsStart 2021-02

  University Hospital, Basel, SwitzerlandSwitzerlandNCT04648137

• DMTCompleted
  SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients

  Phase 1 / Phase 2Major Depressive Disorder66 participantsStart 2021-02

  Small Pharma LtdUnited KingdomNCT04673383

• KetamineCompleted
  Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC

  Cancer, Chronic Pain, Neuropathic Pain81 participantsStart 2021-02

  Centre Leon BerardFranceNCT04459234

• PsilocybinCompleted
  Naturalistic Study of Microdosing With Psilocybin

  Cognitive Change, Creativity, Mood Change34 participantsStart 2021-01

  National Council of Scientific and Technical Research, ArgentinaArgentinaNCT05160220

• KetamineCompleted
  Inpatient Single Dose Interventions for Alcohol Use Disorder

  Early phase 1Alcohol Use Disorder, Severe44 participantsStart 2021-01

  Denver Health and Hospital AuthorityUnited StatesNCT04562779

• KetamineCompleted
  Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

  Phase 1Major Depressive Disorder74 participantsStart 2021-01

  National Institute of Mental Health (NIMH)United StatesNCT04711005

• PsilocybinCompleted
  The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density

  Phase 2Major Depressive Disorder, Depression35 participantsStart 2021-01

  Section for Affective Disorders; Northern Stockholm PsychiatrySwedenNCT04630964

• MDMALSDCompleted
  Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects

  Phase 1Healthy24 participantsStart 2021-01

  University Hospital, Basel, SwitzerlandSwitzerlandNCT04516902

• KetamineCompleted
  Ketamine for the Treatment of Opioid Use Disorder and Depression

  Phase 2Depression, Opioid-use Disorder, Opioid Abuse21 participantsStart 2020-12

  Medical University of South CarolinaUnited StatesNCT04177706

• DMTCompleted
  Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects

  Early phase 1Emotions, Mood, Cognitive Function 1, Social34 participantsStart 2020-12

  Psychiatric University Hospital, ZurichSwitzerlandNCT04716335

• KetamineEnrolling by invitation
  Safety and Efficacy of Ketamine Intravenous Infusions in the Treatment of Fibromyalgia

  Fibromyalgia50 participantsStart 2020-11

  Wilderman Medical ClinicCanadaNCT06916403

• KetamineUnknown
  Use of Transmucosal Ketamine in Post Stroke Depression

  Phase 1Post-stroke Depression21 participantsStart 2020-11

  West Virginia UniversityUnited StatesNCT04876066

• EsketamineUnknown
  The Study on the Esketamine in the Treatment of Postherpetic Neuralgia

  Phase 4Postherpetic Neuralgia, Esketamine48 participantsStart 2020-11

  Second Affiliated Hospital, Zhejiang University, School of MedicineChinaNCT04664530

• EsketamineWithdrawn
  Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain

  Phase 2Cancer PainStart 2020-11

  University Hospital, Basel, SwitzerlandSwitzerlandNCT04666623

• KetamineUnknown
  Lidocaine and Magnesium and Ketamine in Gynecological Surgery

  Pain, Postoperative, Pain, Acute, Pain, Chronic90 participantsStart 2020-11

  Aretaieion University HospitalGreeceNCT04622904

• KetamineCompleted
  Ketamine to Prevent PPD After Cesarean

  Phase 3Postpartum Depression25 participantsStart 2020-11

  Washington University School of MedicineUnited StatesNCT04227704

• EsketamineCompleted
  A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

  Phase 4Depressive Disorder, Treatment-Resistant477 participantsStart 2020-11

  Janssen Research & Development, LLCUnited StatesNCT04599855

• IbogaineCompleted
  Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification

  Phase 2Drug Dependence, Drug Use Disorders, Opioid Dependence20 participantsStart 2020-10

  International Center for Ethnobotanical Education, Research, and ServiceSpainNCT04003948

• KetamineCompleted
  Ketamine for Older Adults Pilot

  Phase 4Treatment Resistant Depression, Refractory Depression, Therapy-Resistant Depression25 participantsStart 2020-10

  Washington University School of MedicineCanada + 1 moreNCT04504175

• LSDCompleted
  Effect of Ketanserin After LSD Administration

  Phase 1Healthy24 participantsStart 2020-10

  University Hospital, Basel, SwitzerlandSwitzerlandNCT04558294

• KetamineCompleted
  Ketamine Treatment Effects on Synaptic Plasticity in Depression

  Phase 4Major Depressive Disorder9 participantsStart 2020-10

  New York State Psychiatric InstituteUnited StatesNCT04091971

• EsketamineUnknown
  Imaging Neural Correlates of Ketamine Using PET/MR

  Phase 1Major Depressive Disorder65 participantsStart 2020-10

  Medical University of ViennaAustriaNCT04587778

• KetamineCompleted
  A Comparison of Gabapentin and Ketamine in Acute and Chronic Pain After Inguinal Hernia Repair

  Chronic Pain Following Surgical Procedure for Cancer60 participantsStart 2020-10

  University Tunis El ManarTunisiaNCT04700592

• EsketamineCompleted
  An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives

  Phase 3Depression41 participantsStart 2020-09

  Janssen-Cilag, S.A.MexicoNCT04476446

• MDMACompleted
  A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)

  Phase 3Posttraumatic Stress Disorder121 participantsStart 2020-09

  Resilient PharmaceuticalsIsrael, United StatesNCT04077437

• PsilocybinUnknown
  The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder

  Phase 2Major Depressive Disorder30 participantsStart 2020-09

  Maryland Oncology Hematology, PAUnited StatesNCT04593563

• EsketamineCompleted
  The Effects of Intraoperative Esketamine on Postoperative Pain and Mood in Patients With Inflammatory Bowel Disease

  Phase 4Crohn Disease, Depression, Esketamine120 participantsStart 2020-09

  Jinling Hospital, ChinaChinaNCT05506787

• KetamineCompleted
  Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality

  Treatment Resistant Depression36 participantsStart 2020-09

  Assiut UniversityEgyptNCT04101474

• EsketamineCompleted
  A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder

  Phase 3Depressive Disorder, Major676 participantsStart 2020-08

  Janssen-Cilag International NVArgentina, Austria, Belgium + 21 moreNCT04338321

• PsilocybinCompleted
  The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression

  Phase 2Treatment Resistant Depression19 participantsStart 2020-08

  COMPASS PathwaysIreland, United StatesNCT04739865

• KetamineCompleted
  Ketamine for Acute Pain Management After Trauma

  Phase 4Trauma Injury, Pain, Opioid Use305 participantsStart 2020-07

  The University of Texas Health Science Center, HoustonUnited StatesNCT04129086

• KetamineWithdrawn
  Low Dose Ketamine Infusion for the Treatment of Resistant Depression

  DepressionStart 2020-06

  Loma Linda UniversityUnited StatesNCT04283058

• MDMACompleted
  Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study

  Phase 2PTSD21 participantsStart 2020-06

  MAPS Europe B.V.Czechia, Germany, Netherlands + 2 moreNCT04030169

• PsilocybinCompleted
  Clinical and Mechanistic Effects of Psilocybin in Alcohol Addicted Patients

  Phase 2Alcohol Use Disorder37 participantsStart 2020-06

  University of ZurichSwitzerlandNCT04141501

• PsilocybinLSDActive, not recruiting
  Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment

  Major Depressive Disorder (MDD), Anxiety Disorders, Substance Use Disorder (SUD)376 participantsStart 2020-06

  University Hospital, GenevaSwitzerlandNCT07164287

• PsilocybinLSDMescalineCompleted
  Comparative Acute Effects of LSD, Psilocybin and Mescaline

  Phase 1Healthy32 participantsStart 2020-05

  University Hospital, Basel, SwitzerlandSwitzerlandNCT04227756

• KetamineWithdrawn
  Intravenous Ketamine Effects on Functional Neuroanatomy

  Phase 1DepressionStart 2020-05

  Neurological Associates of West Los AngelesUnited StatesNCT04205890

• KetamineUnknown
  Study to Assess the Effects of Intranasal Ketamine Along With rTMS for Patients With Treatment-resistant Major Depressive Disorder (TRD)

  Phase 4Major Depressive Disorder20 participantsStart 2020-05

  University of CincinnatiNCT04352621

• KetamineCompleted
  A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health

  Phase 4Depression, Anxiety, Post Traumatic Stress Disorder1806 participantsStart 2020-03

  Field Trip HealthCanada + 1 moreNCT05604794

• KetamineCompleted
  Opioid Free vs Opioid Based Anesthesia for Laparoscopic Sleeve Gastrectomy

  Phase 4Obesity, Postoperative Pain, Postoperative Nausea59 participantsStart 2020-02

  Medical University of WarsawPolandNCT04260659

• PsilocybinCompleted
  A Study of Psilocybin for Major Depressive Disorder (MDD)

  Phase 2Depressive Disorder, Major347 participantsStart 2020-01

  Usona InstituteUnited StatesNCT03866174

• PsilocybinTerminated
  Prophylactic Effects of Psilocybin on Chronic Cluster Headache

  Phase 1 / Phase 2Cluster Headache10 participantsStart 2020-01

  Gitte Moos KnudsenDenmarkNCT04280055

• KetamineTerminated
  Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department

  Phase 3Suicide, Suicide Threat, Depression Severe1 participantsStart 2020-01

  Naval Medical Center Camp LejeuneUnited StatesNCT04260607

• KetamineTerminated
  Ketamine Interleaved With Electroconvulsive Therapy for Depression

  Phase 1Depression3 participantsStart 2020-01

  St Patrick's Hospital, IrelandIrelandNCT04082858

• KetamineWithdrawn
  Intranasal Ketamine for Suicidal Ideation in Veterans

  Early phase 1Suicidal IdeationStart 2020-01

  Bronx Veterans Medical Research Foundation, IncUnited StatesNCT03788694

• KetamineCompleted
  The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women

  Early phase 1Ketamine, Lactation4 participantsStart 2019-12

  The Ketamine Research FoundationUnited StatesNCT04285684

• KetamineTerminated
  Ketamine + Cognitive Training for Suicidality in the Medical Setting: Pilot

  Phase 4Suicide, Attempted16 participantsStart 2019-12

  Rebecca PriceUnited StatesNCT04154150

• KetamineTerminated
  Perioperative Ketamine in Opioid-Tolerant Patients Undergoing Lumbar Spine Surgery

  Phase 2Opioid Dependence, Chronic Pain1 participantsStart 2019-12

  Jacques E. ChellyUnited StatesNCT04220489

• KetamineCompleted
  A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders

  Treatment Resistant Depression, Bipolar Depression, Ketamine80 participantsStart 2019-12

  Medical University of GdanskPolandNCT04226963

• EsketamineWithdrawn
  A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression

  Phase 3Depressive Disorder, Treatment-ResistantStart 2019-12

  Janssen-Cilag International NVNCT03852160

• KetamineWithdrawn
  Single-dose Ketamine for the Reduction of Pain and Depression in the Emergency Department

  Phase 2 / Phase 3Acute Pain, DepressionStart 2019-12

  Maria PacellaNCT03436121

• DMTCompleted
  Clinical Study of GH001 in Depression

  Phase 1 / Phase 2Treatment Resistant Depression, Major Depressive Disorder, Depression16 participantsStart 2019-11

  GH Research Ireland LimitedNetherlandsNCT04698603

• LSDCompleted
  LSD Therapy for Persons Suffering From Major Depression

  Phase 2Major Depressive Disorder60 participantsStart 2019-11

  University Hospital, Basel, SwitzerlandSwitzerlandNCT03866252

• MDMACompleted
  Effect of Methylenedioxymethamphetamine (MDMA) (Serotonin Release) on Fear Extinction

  Early phase 1Healthy30 participantsStart 2019-10

  University Hospital, Basel, SwitzerlandSwitzerlandNCT03527316

• KetamineCompleted
  Effectiveness of Ketamine for Depression and Suicidal Ideation in the Emergency Department

  Phase 4Depression, Depression Severe, Depression Acute29 participantsStart 2019-10

  MercyOne Des Moines Medical CenterUnited StatesNCT04266288

• KetamineCompleted
  Ketamine to Improve Recovery After Cesarean Delivery - Part 1

  Phase 2Obstetric Pain, Postpartum Depression, Breastfeeding8 participantsStart 2019-10

  Grace Lim, MD, MSUnited StatesNCT04037085

• KetamineCompleted
  EEG Characteristics in ECT

  Early phase 1Electroconvulsive Therapy, Direct Current Electroencephalogram, Ketamine11 participantsStart 2019-10

  University of New MexicoUnited StatesNCT04022226

• KetamineCompleted
  Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans

  Phase 1Post-Traumatic Stress Disorders, Major Depressive Disorder67 participantsStart 2019-09

  University of MinnesotaUnited StatesNCT04032301

• KetamineCompleted
  Ketamine or Placebo in Patients With Major Depression and Advanced Cancer

  Phase 1 / Phase 2Major Depressive Disorder, Advanced Cancer19 participantsStart 2019-09

  Instituto Nacional de Cancerologia de MexicoMexicoNCT04471818

• PsilocybinCompleted
  Effects of Psilocybin in Anorexia Nervosa

  Phase 1Anorexia Nervosa22 participantsStart 2019-08

  Johns Hopkins UniversityUnited StatesNCT04052568

• KetamineCompleted
  Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery

  Phase 4Major Depressive Disorder, Surgery, Orthopedic Disorder45 participantsStart 2019-08

  Stanford UniversityUnited StatesNCT03861988

• MDMACompleted
  Effects of Drugs on Responses to Brain and Emotional Processes

  Early phase 1Autism Spectrum Disorder, Healthy22 participantsStart 2019-08

  University of ChicagoUnited StatesNCT04053036

• KetamineWithdrawn
  Endogenous Opioid Modulation by Ketamine

  Phase 3Major Depressive DisorderStart 2019-08

  University of UtahUnited StatesNCT03051945

• KetamineTerminated
  Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy

  Phase 2 / Phase 3Major Depressive Disorder3 participantsStart 2019-07

  Yale UniversityUnited StatesNCT03889756

• KetamineUnknown
  Ketamine for Mood Disorders With Suicidal Ideation

  Early phase 1Depressive Disorder, Major, Suicidal Ideation20 participantsStart 2019-07

  The Miriam HospitalUnited StatesNCT04099771

• KetamineCompleted
  Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine

  Phase 2 / Phase 3Depressive Disorder, Treatment-Resistant9 participantsStart 2019-06

  Dan IosifescuUnited StatesNCT04216888

• KetamineUnknown
  NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression

  Phase 3Bipolar Depression, Suicidal Ideation150 participantsStart 2019-06

  NeuroRx, Inc.United StatesNCT03396601

• KetamineUnknown
  Open Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults With Bipolar Disorder

  Bipolar Disorder20 participantsStart 2019-06

  Mclean HospitalUnited StatesNCT05209217

• KetamineTerminated
  The Role of HNKs in the Antidepressant Effect of Ketamine

  Phase 1Major Depressive Disorder8 participantsStart 2019-05

  Columbia UniversityUnited StatesNCT03977675

• KetamineCompleted
  Ketamine Infusion Therapy for the Treatment of PTSD in Paramedics

  Stress Disorders, Post-Traumatic, Anxiety Disorders7 participantsStart 2019-05

  Klarisana Physician Services PLLCUnited StatesNCT03947099

• KetamineWithdrawn
  Alcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or Ketamine

  Phase 4Alcohol Withdrawal SyndromeStart 2019-04

  Santa Barbara Cottage HospitalNCT03788889

• KetamineCompleted
  Ketamine and Prolonged Exposure in PTSD

  Phase 1 / Phase 2Post-traumatic Stress Disorder12 participantsStart 2019-04

  Minneapolis Veterans Affairs Medical CenterUnited StatesNCT03960658

• KetamineWithdrawn
  ED Treatment of Suicidal Patients With Ketamine Infusion

  Phase 2Suicide, Suicidal IdeationStart 2019-04

  University of California, DavisUnited StatesNCT03502551

• PsilocybinTerminated
  Effects of Psilocybin in Concussion Headache

  Phase 1Post-Traumatic Headache12 participantsStart 2019-03

  Yale UniversityUnited StatesNCT03806985

• EsketamineCompleted
  Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression

  Phase 2Bipolar Depression88 participantsStart 2019-03

  Celon Pharma SAPolandNCT03965871

• PsilocybinLSDCompleted
  Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin

  Early phase 1Healthy28 participantsStart 2019-03

  University Hospital, Basel, SwitzerlandSwitzerlandNCT03604744

• DMTCompleted
  Safety of GH001 in Healthy Volunteers

  Phase 1Healthy Volunteers22 participantsStart 2019-03

  GH Research Ireland LimitedNetherlandsNCT04640831

• PsilocybinCompleted
  Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept

  Phase 2Depressive Disorder, Major55 participantsStart 2019-03

  University of ZurichSwitzerlandNCT03715127

• KetamineTerminated
  Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression

  Phase 2Post Partum Depression1 participantsStart 2019-03

  The University of Texas Health Science Center, HoustonUnited StatesNCT04011592

• PsilocybinCompleted
  The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

  Phase 2Treatment Resistant Depression233 participantsStart 2019-03

  COMPASS PathwaysCanada + 9 moreNCT03775200

• EsketamineCompleted
  Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression

  Phase 2Major Depressive Disorder88 participantsStart 2019-02

  Celon Pharma SAPolandNCT03965858

• KetamineUnknown
  The Effect of Intravenous Ketamine on Non Suicidal Self Injuries.

  Phase 1 / Phase 2Non Suicidal Self Injury30 participantsStart 2019-02

  Tel-Aviv Sourasky Medical CenterIsraelNCT04242914

• KetamineCompleted
  Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

  Phase 2Depressive Disorder, Treatment-Resistant70 participantsStart 2019-02

  Novartis PharmaceuticalsSpain, United StatesNCT03756129

• PsilocybinCompleted
  Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms

  Phase 2Depressive Disorder, Major59 participantsStart 2019-01

  Imperial College LondonUnited KingdomNCT03429075

• KetamineActive, not recruiting
  Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:

  Early phase 1Major Depressive Disorder, Treatment Resistant Depression, Bipolar Depression18 participantsStart 2019-01

  Mayo ClinicUnited StatesNCT03573349

• PsilocybinCompleted
  Psilocybin for Treatment of Obsessive Compulsive Disorder

  Phase 1Obsessive-compulsive Disorder (OCD)15 participantsStart 2019-01

  University of ArizonaUnited StatesNCT03300947

• KetamineUnknown
  Ketamine Co-induction for Patients With Major Depressive Disorder

  Phase 4Ketamine, Depression, Anesthesia50 participantsStart 2018-12

  University of SaskatchewanNCT03666494

• KetamineCompleted
  Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial

  Phase 1Depressive Disorder, Major, Post Traumatic Stress Disorder, Bipolar Disorder13 participantsStart 2018-11

  Yale UniversityUnited StatesNCT03367533

• MDMACompleted
  A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)

  Phase 3Posttraumatic Stress Disorder100 participantsStart 2018-11

  Resilient PharmaceuticalsCanada + 2 moreNCT03537014

• MDMACompleted
  Epigenetics and MDMA-Assisted Psychotherapy for PTSD

  Phase 3PTSD45 participantsStart 2018-11

  University of Southern CaliforniaUnited StatesNCT06189027

• PsilocybinCompleted
  Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.

  Phase 1Obsessive-Compulsive Disorder31 participantsStart 2018-11

  Yale UniversityUnited StatesNCT03356483

• KetamineTerminated
  Acute Pain Management in Patients on Opioid Replacement Therapy

  Phase 1Opioid-use Disorder, Pain, Acute1 participantsStart 2018-10

  University of California, San FranciscoUnited StatesNCT03933865

• KetamineSuspended
  Ketamine Versus Electroconvulsive Therapy in Depression

  Phase 3Depressive Disorder, Major, Bipolar Depression240 participantsStart 2018-10

  University of OttawaCanadaNCT03674671

• KetamineUnknown
  Evaluation of Schemes of Administration of Intravenous Ketamine in Depression

  Phase 3Treatment Resistant Depression30 participantsStart 2018-10

  National Institute of Neurology and Neurosurgery, MexicoMexicoNCT03742557

• KetamineUnknown
  Using a Low Dose of Ketamine vs. Active Placebo in Treating Severe Depression and Suicide

  Major Depressive Disorder48 participantsStart 2018-09

  Taipei Veterans General Hospital, TaiwanTaiwanNCT03666390

• EsketamineCompleted
  Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine

  Treatment Resistant Depression10 participantsStart 2018-09

  Psych AtlantaUnited StatesNCT04856124

• KetamineUnknown
  Ketamine for Treatment Resistant MDD

  Depressive Disorder, Major20 participantsStart 2018-09

  Hadassah Medical OrganizationIsraelNCT04021433

• KetamineWithdrawn
  Ketamine Sickle Cell Disease

  Phase 3SC Disease, Pain, ChronicStart 2018-09

  University of South FloridaNCT03502421

• PsilocybinKetamineUnknown
  Psilocybin and Depression

  Phase 2Severe Depression60 participantsStart 2018-09

  University of HelsinkiNCT03380442

• KetamineCompleted
  Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care

  Phase 2Depression, Cancer, Palliative Care22 participantsStart 2018-07

  University Health Network, TorontoCanadaNCT03410446

• KetamineCompleted
  Postpartum Perineal Pain After Obstetric Anal Sphincter Injuries

  Phase 4Pain, Postpartum Depression67 participantsStart 2018-06

  Northwestern UniversityUnited StatesNCT03470675

• EsketamineCompleted
  A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

  Phase 3Depressive Disorder, Treatment-Resistant252 participantsStart 2018-05

  Janssen Research & Development, LLCChina, United StatesNCT03434041

• LSDCompleted
  Mood Effects of Serotonin Agonists

  Phase 1Healthy80 participantsStart 2018-05

  University of ChicagoUnited StatesNCT03790358

• KetamineCompleted
  Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse

  Phase 3Suicidal Ideation, Depression, Alcohol Abuse33 participantsStart 2018-05

  The University of Texas Health Science Center, HoustonUnited StatesNCT03539887

• MDMAUnknown
  Bristol Imperial MDMA in Alcoholism Study

  Phase 1Alcohol Use Disorder20 participantsStart 2018-04

  Imperial College LondonUnited KingdomNCT04158778

• KetamineCompleted
  Effect of Ketamine in Depressive Symptoms of Elderly Patients With Visual Impairment.

  Depression in Old Age, Ketamine90 participantsStart 2018-04

  Instituto Mexicano del Seguro SocialMexicoNCT03473431

• KetamineUnknown
  Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression

  Phase 4Depressive Disorder88 participantsStart 2018-04

  University of Sao PauloBrazilNCT04234776

• MDMACompleted
  Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada)

  Phase 2Posttraumatic Stress Disorder4 participantsStart 2018-03

  Resilient PharmaceuticalsCanadaNCT03485287

• PsilocybinActive, not recruiting
  Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder

  Phase 1Major Depressive Disorder18 participantsStart 2018-02

  Yale UniversityUnited StatesNCT03554174

• KetamineUnknown
  Ketamine's Efficiency in the Treatment of Chronic Pain: Kynurenin Pathway

  Phase 3Neuralgia, Chronic Pain, Inflammation48 participantsStart 2018-02

  RedarFranceNCT03513822

• KetamineTerminated
  Ketamine in Borderline Personality Disorder

  Phase 2Borderline Personality Disorder22 participantsStart 2018-02

  Yale UniversityUnited StatesNCT03395314

• KetamineUnknown
  Respiratory Depression During an Analgosedation Combining Remifentanil and Ketamine in TCI for Oocyte Retrieval

  Oocyte Retrieval, Sedation, Conscious, Ventilatory Depression20 participantsStart 2018-02

  Erasme University HospitalBelgiumNCT03458143

• KetamineWithdrawn
  Ketamine vs. Placebo as Adjunctive Therapies for Severe Alcohol Withdrawal

  Phase 4Alcohol WithdrawalStart 2018-02

  University of Colorado, DenverUnited StatesNCT02823977

• KetamineCompleted
  Sequential Therapy for the Treatment of Severe Bipolar Depression.

  Phase 2Bipolar Depression, Suicidal Ideas, Suicidal Ideation22 participantsStart 2018-01

  NeuroRx, Inc.United StatesNCT02974010

• KetamineCompleted
  Ketamine Infusion for Comorbid PTSD and Chronic Pain

  Phase 3PTSD, Chronic Pain41 participantsStart 2018-01

  VA Ann Arbor Healthcare SystemUnited StatesNCT04322968

• PsilocybinCompleted
  Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors

  Phase 1Distress, Depression, Grief30 participantsStart 2018-01

  Joshua WoolleyUnited StatesNCT02950467

• KetamineWithdrawn
  Ketamine Continuous Infusion on Opioid Consumption and Pain Management in Severe Burned Patients

  Phase 3Pain, BurningStart 2018-01

  University of Sao Paulo General HospitalBrazilNCT02860117

• KetamineTerminated
  RCT: Fentanyl Plus Ketamine Versus Fentanyl Alone for Acute Burn Pain

  Phase 4Acute Pain, Wound Care, Posttraumatic Stress Disorder4 participantsStart 2017-12

  Johns Hopkins UniversityUnited StatesNCT03305055

• Salvinorin ACompleted
  Effects of Salvinorin A on Brain Function

  Phase 1 / Phase 2Drug Effect13 participantsStart 2017-12

  Johns Hopkins UniversityUnited StatesNCT03418714

• KetamineCompleted
  Intravenous Ketamine Plus Neurocognitive Training for Depression

  Phase 1 / Phase 2Depression154 participantsStart 2017-12

  Rebecca PriceUnited StatesNCT03237286

• KetamineWithdrawn
  Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine

  Phase 2Treatment Resistant DepressionStart 2017-11

  William V. Bobo, M.D.United StatesNCT03290963

• LSDCompleted
  Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)

  Early phase 1Healthy16 participantsStart 2017-11

  University Hospital, Basel, SwitzerlandSwitzerlandNCT03321136

• KetamineCompleted
  Low-dose Ketamine and Postpartum Depression in Parturients With Prenatal Depression

  Phase 4Perinatal Depression, Ketamine, Cesarean Delivery64 participantsStart 2017-11

  Peking University First HospitalChinaNCT03336541

• MDMACompleted
  Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD

  Phase 2PTSD38 participantsStart 2017-11

  Resilient PharmaceuticalsUnited StatesNCT03282123

• PsilocybinCompleted
  Psilocybin for the Treatment of Migraine Headache

  Phase 1Migraine Headache14 participantsStart 2017-11

  Yale UniversityUnited StatesNCT03341689

• KetamineCompleted
  Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy

  Phase 3Anesthesia, General Anesthesia, Analgesics, Opioid50 participantsStart 2017-10

  University of SaskatchewanCanadaNCT02987985

• EsketamineCompleted
  Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

  Phase 2Depressive Disorder, Major147 participantsStart 2017-10

  Janssen Research & Development, LLCBelgium, Brazil, Bulgaria + 6 moreNCT03185819

• KetamineCompleted
  Ketamine With Multilevel Paravertebral Block for Post Video-assisted Thoracic Surgery Pain

  Phase 4Pain, Acute, Pain, Chronic, Pain, Neuropathic32 participantsStart 2017-09

  Mahidol UniversityThailandNCT03280017

• KetamineCompleted
  A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)

  Phase 4Depression51 participantsStart 2017-09

  Massachusetts General HospitalUnited StatesNCT03149991

• KetamineCompleted
  Ketamine as an Adjunctive Therapy for Major Depression

  Phase 1Major Depressive Episode, Unipolar Depression, Bipolar Depression25 participantsStart 2017-09

  St Patrick's Hospital, IrelandIrelandNCT03256162

• KetamineUnknown
  Lidocaine-Ketamine for Management of Chronic Pain

  Chronic Pain Syndrome72 participantsStart 2017-09

  Hamilton Health Sciences CorporationNCT03249025

• PsilocybinCompleted
  Effects of Psilocybin in Major Depressive Disorder

  Phase 2Major Depressive Disorder27 participantsStart 2017-08

  Johns Hopkins UniversityUnited StatesNCT03181529

• KetamineCompleted
  Ketamine and Postoperative Depressive Symptom-PASSION

  Phase 2 / Phase 3Ketamine; Depressive Symptom; Neurosurgery; Perioperative Period84 participantsStart 2017-07

  Beijing Tiantan HospitalChinaNCT03086148

• PsilocybinCompleted
  Persisting Effects of Psilocybin

  Phase 1 / Phase 2Healthy13 participantsStart 2017-07

  Johns Hopkins UniversityUnited StatesNCT02971605

• KetamineTerminated
  Ketamine and Magnesium in Post-operative Pain Control in Patients Treated With Opioids

  Phase 1Chronic Pain20 participantsStart 2017-07

  Milton S. Hershey Medical CenterUnited StatesNCT02940509

• KetamineCompleted
  Prevention of Post Mastectomy With Intraoperative Ketamine

  Early phase 1Pain, Postoperative, Post-Mastectomy Chronic Pain Syndrome264 participantsStart 2017-07

  Brigham and Women's HospitalUnited StatesNCT03090776

• LSDCompleted
  LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders

  Phase 2Patients, Anxiety Disorders46 participantsStart 2017-06

  University Hospital, Basel, SwitzerlandSwitzerlandNCT03153579

• EsketamineCompleted
  54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

  Phase 3Depressive Disorder, Major230 participantsStart 2017-06

  Janssen Research & Development, LLCCanada + 11 moreNCT03097133

• EsketamineCompleted
  54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

  Phase 3Depressive Disorder, Major226 participantsStart 2017-06

  Janssen Research & Development, LLCBulgaria, Estonia, Germany + 8 moreNCT03039192

• KetamineCompleted
  The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.

  Phase 4Major Depression, Bipolar I Disorder, Bipolar II Disorder75 participantsStart 2017-06

  Mayo ClinicUnited StatesNCT03156504

• KetamineCompleted
  Dexamethasone and Ketamine on Change of Postoperative Mood

  Phase 4Depressive Symptoms93 participantsStart 2017-05

  Wonkwang University HospitalSouth KoreaNCT03194594

• KetamineCompleted
  Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain

  Phase 3Chronic Pain106 participantsStart 2017-05

  Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterUnited StatesNCT02920528

• KetamineUnknown
  Investigation of Antidepressant Efficacy of Oral Ketamine Treatment

  Phase 2Major Depressive Episode60 participantsStart 2017-04

  Medical University of ViennaAustriaNCT02992496

• KetamineCompleted
  ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)

  Phase 2 / Phase 3Treatment Resistant Depression, Electroconvulsive Therapy, ECT403 participantsStart 2017-04

  Bo HuUnited StatesNCT03113968

• MDMACompleted
  Evaluation of MDMA on Startle Response

  Phase 1Startle Response34 participantsStart 2017-03

  Resilient PharmaceuticalsUnited StatesNCT03181763

• KetamineTerminated
  The Effect of Ketamine on the Length of Hospital Stay of Patients Hospitalized With Suicidal Ideation.

  Phase 4Suicidal Ideation4 participantsStart 2017-03

  Allen RichertUnited StatesNCT02997722

• KetamineCompleted
  Ketamine and Nitroprusside for Depression

  Phase 2Depression40 participantsStart 2017-02

  Icahn School of Medicine at Mount SinaiUnited StatesNCT03102736

• MDMALSDCompleted
  Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing

  Early phase 1Healthy28 participantsStart 2017-02

  University Hospital, Basel, SwitzerlandSwitzerlandNCT03019822

• KetamineWithdrawn
  The Impact of Ketamine on the Reward Circuitry of Suicidal Patients

  Phase 3Suicidal Ideation, SuicideStart 2017-02

  Massachusetts General HospitalUnited StatesNCT02532153

• KetamineCompleted
  Open Label Ketamine Treatment for Major Depressive Disorder in Veterans

  Phase 2Major Depressive Disorder11 participantsStart 2017-01

  VA Connecticut Healthcare SystemUnited StatesNCT03053830

• KetamineCompleted
  Study of Oral Ketamine Versus Placebo for Treating Depression in Patients Undergoing Treatment for Cancer

  Early phase 1Cancer, Depression4 participantsStart 2016-12

  Scott A. Irwin, MD, PhDUnited StatesNCT02836288

• EsketamineCompleted
  A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

  Phase 2Depression202 participantsStart 2016-12

  Janssen Pharmaceutical K.K.JapanNCT02918318

• PsilocybinCompleted
  Psilocybin for the Treatment of Cluster Headache

  Phase 1Cluster Headache25 participantsStart 2016-12

  Yale UniversityUnited StatesNCT02981173

• KetamineCompleted
  Ketamine Infusion Therapy for PTSD in Combat Veterans

  Stress Disorders, Post-Traumatic30 participantsStart 2016-11

  Klarisana Physician Services PLLCUnited StatesNCT03088384

• KetamineTerminated
  The UTHealth Ketamine Project

  Phase 2Treatment Resistant Depression, Major Depressive Disorder, Bipolar Disorder10 participantsStart 2016-11

  The University of Texas Health Science Center, HoustonUnited StatesNCT02882711

• KetamineCompleted
  Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients

  Phase 2Treatment Resistant Depression9 participantsStart 2016-10

  The University of Texas Health Science Center, HoustonUnited StatesNCT02935595

• EsketamineCompleted
  A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder

  Phase 1Depressive Disorder, Major27 participantsStart 2016-10

  Janssen Research & Development, LLCNetherlandsNCT02919579

• KetamineCompleted
  Ketamine for Reduction of Alcoholic Relapse

  Phase 2Primary Alcohol Use Disorder96 participantsStart 2016-10

  University College, LondonUnited KingdomNCT02649231

• KetamineCompleted
  Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease

  Phase 2 / Phase 3Depression42 participantsStart 2016-09

  University Hospital, LilleFranceNCT02783430

• KetamineUnknown
  Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression

  Phase 4Depression48 participantsStart 2016-09

  University of ManitobaCanadaNCT02924090

• KetamineCompleted
  Understanding How Ketamine Brings About Rapid Improvement in OCD

  Phase 2Obsessive-Compulsive Disorder120 participantsStart 2016-08

  Stanford UniversityUnited StatesNCT02624596

• KetamineWithdrawn
  Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers

  Early phase 1Head and Neck Cancer, Pancreatic Cancer, DepressionStart 2016-08

  Cedars-Sinai Medical CenterUnited StatesNCT02442739

• KetamineWithdrawn
  A Study to Decrease Suicidal Thinking Using Ketamine

  Phase 3Depression, SuicideStart 2016-08

  United States Naval Medical Center, San DiegoUnited StatesNCT02418702

• KetamineUnknown
  Emergency Ketamine Treatment of Suicidal Ideation

  Phase 2 / Phase 3Depression, Suicidal Ideation, Suicidal Impulses60 participantsStart 2016-08

  University of CincinnatiUnited StatesNCT02183272

• KetamineUnknown
  OBSERVATIONAL STUDY OF THE MANAGEMENT OF PATIENTS WITH CHRONIC PAIN

  Chronic Pain1000 participantsStart 2016-07

  University Hospital, Clermont-FerrandFranceNCT03319238

• MDMACompleted
  MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD

  Phase 1 / Phase 2Posttraumatic Stress Disorder12 participantsStart 2016-07

  Resilient PharmaceuticalsUnited StatesNCT02876172

• KetamineTerminated
  Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects

  Depression8 participantsStart 2016-07

  Massachusetts General HospitalUnited StatesNCT02669043

• EsketamineCompleted
  A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

  Phase 3Depressive Disorder, Treatment-Resistant1148 participantsStart 2016-06

  Janssen Research & Development, LLCCanada + 25 moreNCT02782104

• MDMACompleted
  Effect of Stimulant Drugs on Social Perception

  Phase 1Healthy, MDMA ('Ecstasy')36 participantsStart 2016-06

  University of ChicagoUnited StatesNCT03790618

• KetamineUnknown
  D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression

  Phase 4Treatment Resistant Depression60 participantsStart 2016-06

  Sheba Medical CenterIsraelNCT02772211

• KetamineCompleted
  Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder

  Phase 2Major Depressive Disorder, Alcohol Use Disorder5 participantsStart 2016-05

  VA Connecticut Healthcare SystemNCT03658330

• KetamineCompleted
  CAP-Ketamine for Antidepressant Resistant PTSD

  Phase 2PTSD, Posttraumatic Stress Disorder163 participantsStart 2016-04

  VA Office of Research and DevelopmentUnited StatesNCT02655692

• KetamineActive, not recruiting
  Imaging SV2A in Mood Disorders

  Major Depressive Disorder, Post-Traumatic Stress Disorder130 participantsStart 2016-04

  Yale UniversityUnited StatesNCT02734602

• KetamineCompleted
  Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia

  Depression, Delirium, Seizures17 participantsStart 2016-04

  Washington University School of MedicineUnited StatesNCT02761330

• KetamineCompleted
  Intra-nasal vs. Intra-venous Ketamine Administration

  Phase 4Major Depressive Disorder45 participantsStart 2016-04

  Shalvata Mental Health CenterIsraelNCT02644629

• KetamineCompleted
  Ketamine for Depression: An MRI Study

  Phase 4Depression, Anxious Depression, Major Depressive Disorder25 participantsStart 2016-03

  Massachusetts General HospitalUnited StatesNCT02544607

• KetamineCompleted
  Ketamine Anesthesia for Improvement of Depression in ECT

  Major Depressive Disorder52 participantsStart 2016-03

  VA Puget Sound Health Care SystemUnited StatesNCT02752724

• KetamineCompleted
  Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects

  Phase 2Depression23 participantsStart 2016-03

  Yale UniversityUnited StatesNCT02487485

• KetamineCompleted
  Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.

  Early phase 1Major Depressive Disorder, Bipolar I Disorder, Bipolar II Disorder9 participantsStart 2016-01

  Sunnybrook Health Sciences CentreCanadaNCT02593643

• KetamineTerminated
  Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms

  Depression, Major Depressive Disorder12 participantsStart 2015-12

  The University of Texas Health Science Center at San AntonioUnited StatesNCT02422303

• KetamineTerminated
  Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy

  Phase 2Posttraumatic Stress Disorder28 participantsStart 2015-12

  Yale UniversityUnited StatesNCT02727998

• KetamineTerminated
  Ketamine for Relapse Prevention in Recurrent Depressive Disorder

  Phase 1Depression, Relapse, Recurrent Depressive Disorder9 participantsStart 2015-12

  St Patrick's Hospital, IrelandIrelandNCT02661061

• KetamineUnknown
  Ketamine and Neuropathic Pain

  Phase 2Neuropathic Pain22 participantsStart 2015-11

  University Hospital, Clermont-FerrandFranceNCT02467517

• LSDCompleted
  A Dose-Ranging Study of 50 µg to 100 µg LSD in Healthy Volunteers

  Phase 1Healthy32 participantsStart 2015-10

  Eleusis TherapeuticsUnited KingdomNCT05674669

• EsketamineCompleted
  A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

  Phase 3Depressive Disorder, Treatment-Resistant719 participantsStart 2015-10

  Janssen Research & Development, LLCCanada + 14 moreNCT02493868

• KetamineCompleted
  Ketamine for Treatment Resistant Late-Life Depression

  Phase 3Treatment Resistant Depressive Disorder33 participantsStart 2015-10

  VA Office of Research and DevelopmentUnited StatesNCT02556606

• KetamineCompleted
  Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy

  Phase 4Depressive Disorder48 participantsStart 2015-10

  University of AlbertaCanadaNCT02579642

• KetamineCompleted
  Ketamine Infusion for Adolescent Depression and Anxiety

  Phase 4Major Depressive Disorder, Anxiety Disorder17 participantsStart 2015-10

  Yale UniversityUnited StatesNCT02579928

• EsketamineCompleted
  A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

  Phase 3Treatment-resistant Depression802 participantsStart 2015-09

  Janssen Research & Development, LLCArgentina, Australia, Austria + 18 moreNCT02497287

• KetamineWithdrawn
  Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder

  Major Depressive DisorderStart 2015-09

  Massachusetts General HospitalUnited StatesNCT01613820

• EsketamineCompleted
  A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

  Phase 3Depressive Disorder, Treatment-Resistant139 participantsStart 2015-08

  Janssen Research & Development, LLCBelgium, Brazil, Bulgaria + 9 moreNCT02422186

• KetamineSuspended
  Intraoperative Ketamine on Chronic Pain After Mastectomy

  Phase 4Chronic Pain135 participantsStart 2015-08

  The University of Hong KongHong KongNCT02729805

• EsketamineCompleted
  A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

  Phase 3Treatment-resistant Depression346 participantsStart 2015-08

  Janssen Research & Development, LLCCanada + 8 moreNCT02417064

• EsketamineCompleted
  A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

  Phase 3Treatment-resistant Depression236 participantsStart 2015-08

  Janssen Research & Development, LLCCzechia, Germany, Poland + 2 moreNCT02418585

• KetamineCompleted
  Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression

  Treatment Resistant Depression, Major Depressive Disorder, Severe Depression15 participantsStart 2015-08

  The Cleveland ClinicUnited StatesNCT02522377

• KetamineCompleted
  Spreading Depolarization and Ketamine Suppression

  Phase 1Cortical Spreading Depolarization, Cortical Spreading Depression, Subarachoid Hemorrhage10 participantsStart 2015-07

  University of New MexicoUnited StatesNCT02501941

• KetamineWithdrawn
  Intranasal Ketamine for Late-Life Depression and Suicidal Ideation

  Phase 4Depression, Suicide, Suicidal IdeationStart 2015-07

  Massachusetts General HospitalNCT02295787

• LSDCompleted
  A Double-blind, Placebo-controlled Study to Evaluate Very Low Dose LSD in Healthy Volunteers Aged 55-75 Years

  Phase 1Healthy Volunteers48 participantsStart 2015-06

  Eleusis TherapeuticsNCT04421105

• KetamineUnknown
  Ketamine for Acute Suicidal Ideation in the Emergency Department: Randomized Controlled Trial

  Suicide53 participantsStart 2015-06

  Brooke Army Medical CenterUnited StatesNCT01892995

• KetamineCompleted
  Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)

  Phase 2 / Phase 3Posttraumatic Stress Disorder (PTSD)30 participantsStart 2015-05

  Icahn School of Medicine at Mount SinaiUnited StatesNCT02397889

• MDMACompleted
  MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness

  Phase 2Anxiety18 participantsStart 2015-05

  Resilient PharmaceuticalsUnited StatesNCT02427568

• PsilocybinCompleted
  Psilocybin-facilitated Treatment for Cocaine Use

  Phase 2Cocaine-Related Disorders40 participantsStart 2015-05

  University of Alabama at BirminghamUnited StatesNCT02037126

• KetamineCompleted
  Ketamine Infusions for PTSD and Treatment-Resistant Depression

  Phase 1Depressive Disorder, Treatment-Resistant, Stress Disorders, Post-Traumatic20 participantsStart 2015-05

  Minneapolis Veterans Affairs Medical CenterUnited StatesNCT02577250

• KetamineCompleted
  miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome

  Phase 2Major Depressive Disorder247 participantsStart 2015-04

  University of Alabama at BirminghamUnited StatesNCT02418195

• KetamineCompleted
  Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression

  Phase 2Treatment-resistant Depression62 participantsStart 2015-04

  VA Office of Research and DevelopmentUnited StatesNCT02360280

• PsilocybinCompleted
  The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals

  Phase 1Religious or Spiritual Problem12 participantsStart 2015-04

  NYU Langone HealthUnited StatesNCT02421263

• KetamineCompleted
  Effects of Ketamine in the Acute Phase of Suicidal Ideation

  Phase 3Suicidal Ideation156 participantsStart 2015-04

  Centre Hospitalier Universitaire de NīmesFranceNCT02299440

• KetamineCompleted
  Ketamine for Depression Relapse Prevention Following ECT

  Early phase 1Depression6 participantsStart 2015-04

  St Patrick's Hospital, IrelandIrelandNCT02414932

• PsilocybinCompleted
  Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion

  Phase 1Healthy24 participantsStart 2015-03

  Johns Hopkins UniversityUnited StatesNCT02243813

• LSDCompleted
  The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers

  Healthy25 participantsStart 2015-03

  Psychiatric University Hospital, ZurichSwitzerlandNCT02451072

• KetamineCompleted
  Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)

  Phase 1 / Phase 2Obsessive-Compulsive Disorder5 participantsStart 2015-03

  New York State Psychiatric InstituteUnited StatesNCT02422290

• KetamineCompleted
  Ketamine Trial for the Treatment of Depression

  Phase 1Unipolar Depression10 participantsStart 2015-03

  The University of New South WalesAustraliaNCT02401139

• KetamineCompleted
  Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine

  Phase 1Depression16 participantsStart 2015-02

  Yale UniversityUnited StatesNCT02289248

• KetamineCompleted
  Ketamine and fMRI for Neuropathic Pain

  Neuralgia39 participantsStart 2015-02

  University Health Network, TorontoCanadaNCT02373449

• KetamineCompleted
  Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder

  Phase 2 / Phase 3Depressive Disorder, Major198 participantsStart 2015-02

  Pouya Movahed RadSwedenNCT02659085

• KetamineCompleted
  Ketamine Infusion for Social Anxiety Disorder

  Early phase 1Social Anxiety Disorder18 participantsStart 2015-01

  Yale UniversityUnited StatesNCT02083926

• KetamineCompleted
  Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder

  Phase 1 / Phase 2Major Depressive Disorder, Alcohol Use Disorder65 participantsStart 2015-01

  VA Office of Research and DevelopmentUnited StatesNCT02461927

• KetamineWithdrawn
  A Randomized, Double-Blind Study of Placebo vs. Ketamine For Use During Dressing Changes in Critically Ill Burn Patients

  Phase 4Thermal Hyperalgesia, Anxiety, PainStart 2015-01

  University of Colorado, DenverUnited StatesNCT02336308

• KetamineCompleted
  Influence of Anesthetic Technique on Acute and Chronic Neuropathic Pain

  Phase 4Acute Pain, Chronic Pain, Hernia10 participantsStart 2015-01

  VA Pittsburgh Healthcare SystemNCT02527083

• KetamineUnknown
  Effect of Subanesthetic Dose of Ketamine Combined With Propofol on Cognitive Function in Depressive Patients Undergoing Electroconvulsive Therapy

  Phase 4Depressive Symptoms, Impaired Cognition, Electroconvulsive Therapy132 participantsStart 2015-01

  First Affiliated Hospital of Chongqing Medical UniversityChinaNCT02305394

• MDMACompleted
  Effects of MDMA on Emotional and Social Memories

  Healthy84 participantsStart 2014-12

  University of ChicagoNCT03050541

• LSDCompleted
  Neuronal Correlates of Altered States of Consciousness

  Early phase 1Healthy24 participantsStart 2014-12

  University Hospital, Basel, SwitzerlandSwitzerlandNCT02308969

• KetamineCompleted
  Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

  Phase 2Treatment Resistant Depression99 participantsStart 2014-12

  Massachusetts General HospitalUnited StatesNCT01920555

• KetamineWithdrawn
  To Test the Potential Efficacy of Repeated Intranasal Administration of Ketamine as a Treatment for PTSD

  Phase 2 / Phase 3PTSDStart 2014-12

  Adriana FederNCT02398136

• KetamineUnknown
  Ultra-low Dose Oral Ketamine for Chronic Pain in the Primary Care Setting

  Phase 3Chronic Pain32 participantsStart 2014-11

  University of WashingtonUnited StatesNCT02303847

• MDMATerminated
  Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD

  Phase 2Posttraumatic Stress Disorder6 participantsStart 2014-10

  Resilient PharmaceuticalsCanadaNCT01958593

• KetamineCompleted
  Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy

  Phase 2 / Phase 3Pain, Postoperative Depression90 participantsStart 2014-10

  NYU Langone HealthUnited StatesNCT02452060

• MDMACompleted
  Abuse Liability and Human Pharmacology of Mephedrone

  Phase 1Amphetamine-Related Disorders12 participantsStart 2014-09

  Parc de Salut MarSpainNCT02232789

• KetamineCompleted
  Ketamine for Depression and Suicide Risk

  Phase 2Depression, Suicide12 participantsStart 2014-09

  Mayo ClinicUnited StatesNCT02094898

• KetamineTerminated
  A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder

  Phase 2Obsessive-Compulsive Disorder1 participantsStart 2014-09

  Mclean HospitalUnited StatesNCT02234011

• KetamineCompleted
  Ketamine in Adolescents With Treatment-Resistant Depression

  Phase 2Major Depressive Disorder14 participantsStart 2014-09

  University of MinnesotaUnited StatesNCT02078817

• KetamineTerminated
  Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD

  Phase 2Obsessive-Compulsive Disorder2 participantsStart 2014-09

  New York State Psychiatric InstituteUnited StatesNCT02206776

• KetamineCompleted
  Retrospective Evaluation of Ketamine Effectiveness for the Treatment of Acute Battlefield Related Pain

  Pain, Acute, Analgesia, Amputation, Traumatic80 participantsStart 2014-08

  Defense and Veterans Center for Integrative Pain ManagementUnited StatesNCT04057989

• KetamineUnknown
  Ketamine Infusions for Major Depression Disorder

  Depressive Disorder, Major10 participantsStart 2014-08

  Sheba Medical CenterIsraelNCT02219867

• KetamineUnknown
  Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy

  Phase 4Depressive Disorder60 participantsStart 2014-07

  Inonu UniversityTurkey (Türkiye)NCT02267980

• PsilocybinCompleted
  A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence

  Phase 2Alcohol Dependence95 participantsStart 2014-06

  NYU Langone HealthUnited StatesNCT02061293

• PsilocybinCompleted
  UW Psilocybin Pharmacokinetics Study

  Phase 1Healthy12 participantsStart 2014-06

  University of Wisconsin, MadisonUnited StatesNCT02163707

• KetamineCompleted
  Biomarkers of Fast Acting Therapies in Major Depression

  Phase 1Major Depressive Disorder60 participantsStart 2014-06

  University of California, Los AngelesUnited StatesNCT02165449

• EsketamineCompleted
  A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide

  Phase 2Major Depressive Disorder68 participantsStart 2014-05

  Janssen Research & Development, LLCUnited StatesNCT02133001

• PsilocybinCompleted
  Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

  Phase 1Healthy40 participantsStart 2014-05

  Johns Hopkins UniversityUnited StatesNCT02145091

• KetamineUnknown
  Clinical Trial of the Use of Ketamine in Treatment Resistant Depression

  Phase 4Depressive Disorder, Treatment-Resistant20 participantsStart 2014-05

  National Institute of Neurology and Neurosurgery, MexicoMexicoNCT02610712

• MDMACompleted
  Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults

  Phase 2Social Anxiety in Autistic Adults12 participantsStart 2014-04

  Resilient PharmaceuticalsUnited StatesNCT02008396

• KetamineCompleted
  Plasma Concentration of Ketamine and Norketamine .

  Chronic Pain12 participantsStart 2014-04

  London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sCanadaNCT02016664

• AyahuascaCompleted
  Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression

  Phase 1 / Phase 2Major Depression35 participantsStart 2014-02

  Universidade Federal do Rio Grande do NorteBrazilNCT02914769

• KetamineTerminated
  A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder

  Phase 2Major Depressive Disorder13 participantsStart 2014-02

  Janssen Research & Development, LLCUnited StatesNCT01957410

• EsketamineCompleted
  A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

  Phase 2Treatment Resistant Depressive Disorder108 participantsStart 2014-01

  Janssen Research & Development, LLCBelgium, Japan, United StatesNCT01998958

• MDMACompleted
  Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD

  Posttraumatic Stress Disorder10 participantsStart 2014-01

  Resilient PharmaceuticalsUnited StatesNCT02102802

• KetamineWithdrawn
  Ketamine Use in Electroconvulsive Therapy

  DepressionStart 2014-01

  Hospital de Clinicas de Porto AlegreBrazilNCT02012335

• KetamineUnknown
  The Effect of Ketamine on Mechanises Underlying Suicidal Ideation and Drug-resistant Major Depression

  Phase 3Suicidal Ideation, Major Depressive Disorder, Healthy Participants100 participantsStart 2014-01

  Tel-Aviv Sourasky Medical CenterIsraelNCT02037503

• KetamineCompleted
  The Effects of Ketamine on Respiratory Stimulation and Transpulmonary Pressures

  Mechanical Ventilation, Airway Patency, Respiratory Depression15 participantsStart 2014-01

  Massachusetts General HospitalUnited StatesNCT01969227

• KetamineUnknown
  Ketamine in Robot-assisted Thyroidectomy

  Thyroid, Acute Pain, Chronic Pain64 participantsStart 2013-12

  Seoul National University HospitalSouth KoreaNCT01997801

• KetamineCompleted
  Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients

  Phase 2Depression21 participantsStart 2013-12

  NYU Langone HealthUnited StatesNCT02106325

• KetamineCompleted
  Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP)

  Phase 2Obsessive-Compulsive Disorder10 participantsStart 2013-12

  New York State Psychiatric InstituteUnited StatesNCT02062658

• PsilocybinCompleted
  Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the Self

  Healthy140 participantsStart 2013-10

  University of ZurichNCT03736980

• MDMACompleted
  Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study

  Early phase 1Healthy, Substance-related Disorder, Mood Disorder24 participantsStart 2013-10

  University Hospital, Basel, SwitzerlandSwitzerlandNCT01951508

• KetamineCompleted
  Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy

  Phase 4Treatment Resistant Depression27 participantsStart 2013-09

  University of SaskatchewanCanadaNCT01935115

• KetamineCompleted
  Ketamine for Suicidality in Bipolar Depression

  Phase 1 / Phase 2Bipolar Disorder, Major Depressive Episode, Suicidal Ideation16 participantsStart 2013-09

  New York State Psychiatric InstituteUnited StatesNCT01944293

• KetamineUnknown
  Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population

  Phase 2Depressive Disorder,, Treatment-Resistant Depression60 participantsStart 2013-09

  Paul J. LamotheMexicoNCT01868802

• KetamineWithdrawn
  Effectiveness of Ketamine in Malignant Neuropathic Pain Relief

  Phase 3Pain, IntractableStart 2013-09

  Haukeland University HospitalNorwayNCT01951911

• KetamineUnknown
  TIMBER Psychotherapy and Ketamine Single Infusion in Chronic PTSD

  PTSD50 participantsStart 2013-08

  The Cooper Health SystemUnited StatesNCT02766192

• KetamineCompleted
  Ketamine Plus Lithium in Treatment-Resistant Depression

  Phase 2Depression34 participantsStart 2013-07

  Icahn School of Medicine at Mount SinaiUnited StatesNCT01880593

• KetamineCompleted
  Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling

  Early phase 1Depression36 participantsStart 2013-07

  Yale UniversityUnited StatesNCT02037035

• LSDCompleted
  Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study

  Early phase 1Healthy16 participantsStart 2013-06

  University Hospital, Basel, SwitzerlandSwitzerlandNCT01878942

• KetamineTerminated
  The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression

  Phase 2Depressive Disorder29 participantsStart 2013-06

  Janssen Research & Development, LLCBelgium, France, Netherlands + 1 moreNCT01809340

• KetamineUnknown
  An Open Prospective Trial of IV Ketamine in Suicidal Adolescents

  Phase 2 / Phase 3Major Depressive Disorder10 participantsStart 2013-06

  Nationwide Children's HospitalUnited StatesNCT02048423

• MDMACompleted
  Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

  Phase 2Posttraumatic Stress Disorder29 participantsStart 2013-05

  Resilient PharmaceuticalsUnited StatesNCT01793610

• PsilocybinCompleted
  Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

  Phase 1Psilocybin, Hallucinogens, Pharmacologic Actions10 participantsStart 2013-05

  Johns Hopkins UniversityUnited StatesNCT01988311

• KetamineCompleted
  Action of Ketamine in Treatment-Resistant Depression

  Phase 2 / Phase 3Treatment-resistant Depression46 participantsStart 2013-05

  University of OttawaCanadaNCT01945047

• KetamineCompleted
  NMDA Antagonists in Bipolar Depression

  Phase 4Bipolar Disorder8 participantsStart 2013-03

  New York State Psychiatric InstituteUnited StatesNCT01833897

• MDMACompleted
  Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD

  Phase 2Posttraumatic Stress Disorder (PTSD)10 participantsStart 2013-01

  Resilient PharmaceuticalsIsraelNCT01689740

• MDMACompleted
  Influence of Bupropion on the Effects of MDMA

  Phase 1Healthy, Substance-related Disorders16 participantsStart 2013-01

  University Hospital, Basel, SwitzerlandSwitzerlandNCT01771874

• KetamineTerminated
  Ketamine in Chronic Kid's (KiCK) Pain

  Phase 2Chronic Pain7 participantsStart 2013-01

  Medical University of South CarolinaUnited StatesNCT01755169

• KetamineCompleted
  Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder

  Major Depressive Disorder37 participantsStart 2013-01

  Massachusetts General HospitalUnited StatesNCT01667926

• KetamineWithdrawn
  Trial of Ketamine and Lithium Therapy in Bipolar Depression

  Phase 2Bipolar DepressionStart 2013-01

  Yale UniversityNCT01768767

• KetamineCompleted
  A Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion

  Phase 2Spinal Fusion129 participantsStart 2012-11

  NYU Langone HealthUnited StatesNCT03274453

• KetamineCompleted
  A Study of Ketamine in Patients With Treatment-resistant Depression

  Phase 2Major Depressive Disorder68 participantsStart 2012-08

  Janssen Research & Development, LLCUnited StatesNCT01627782

• MDMACompleted
  Effects of MDMA and Methylphenidate on Social Cognition

  Early phase 1Social Cognition30 participantsStart 2012-08

  University Hospital, Basel, SwitzerlandSwitzerlandNCT01616407

• KetamineTerminated
  Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer

  Phase 2Cancer, Depression, Anxiety5 participantsStart 2012-08

  Mayo ClinicUnited StatesNCT01680172

• KetamineTerminated
  Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder

  Phase 2 / Phase 3Bipolar Disorder5 participantsStart 2012-07

  Juvenile Bipolar Research FoundationUnited StatesNCT01504659

• EsketamineCompleted
  A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression

  Phase 2Major Depressive Disorder30 participantsStart 2012-06

  Janssen Research & Development, LLCBelgium, Germany, PolandNCT01640080

• KetamineCompleted
  PET Imaging of mGLuR5 With Drug Challenge

  Major Depressive Disorder, Post-Traumatic Stress Disorder (PTSD)79 participantsStart 2012-06

  Yale UniversityUnited StatesNCT01691092

• KetamineTerminated
  Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder

  Phase 1 / Phase 2Obsessive Compulsive Disorder3 participantsStart 2012-06

  Wayne Goodman MDUnited StatesNCT01371110

• KetamineCompleted
  Ketamine in the Treatment of Suicidal Depression

  Phase 4Major Depressive Disorder, Suicidal Ideation82 participantsStart 2012-06

  New York State Psychiatric InstituteUnited StatesNCT01700829

• KetamineCompleted
  Treatment of Suicidal Ideation With Intravenous Ketamine Infusion

  Depression, Suicidal Ideation18 participantsStart 2012-05

  University of Alabama at BirminghamUnited StatesNCT01887990

• KetamineCompleted
  Ketamine Infusion for Treatment-resistant Major Depressive Disorder

  Major Depressive Disorder14 participantsStart 2012-04

  Massachusetts General HospitalUnited StatesNCT01582945

• KetamineCompleted
  Treatment Resistant Depression (Pilot)

  Depressive Disorder, Treatment-Resistant20 participantsStart 2012-04

  Washington University School of MedicineUnited StatesNCT01179009

• KetamineCompleted
  Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks

  Phase 3Major Depressive Disorder25 participantsStart 2012-03

  University Hospital, GrenobleFranceNCT01557712

• KetamineCompleted
  Ketamine for Depression and Alcohol Dependence

  Phase 1Depression, Alcohol Dependence5 participantsStart 2012-03

  Yale UniversityUnited StatesNCT01551329

• KetamineCompleted
  Effects of Sevoflurane and Ketamine on QT in Electroconvulsive Therapy

  Phase 4Major Depression, Electroconvulsive Therapy24 participantsStart 2012-02

  Inonu UniversityTurkey (Türkiye)NCT01870219

• KetamineCompleted
  Ketamine in the Treatment of Depression

  Phase 2Major Depressive Disorder38 participantsStart 2012-02

  Columbia UniversityUnited StatesNCT01558063

• KetamineUnknown
  Study of Ketamine as an Antidepressant in Major Depressive Disorder

  Phase 1 / Phase 2Major Depressive Disorder35 participantsStart 2012-02

  Shi JinyunChinaNCT01573741

• KetamineTerminated
  The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence

  Phase 1 / Phase 2Cocaine Dependence55 participantsStart 2012-02

  New York State Psychiatric InstituteUnited StatesNCT01535937

• PsilocybinCompleted
  Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence

  Phase 2Alcohol Dependence10 participantsStart 2012-01

  University of New MexicoUnited StatesNCT01534494

• PsilocybinWithdrawn
  Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma

  Phase 2Anxiety, Stage IV MelanomaStart 2012-01

  Multidisciplinary Association for Psychedelic StudiesUnited StatesNCT00979693

• KetamineCompleted
  Ketamine For Suicidal Ideation

  Phase 4Suicidal Ideation24 participantsStart 2012-01

  James MurroughUnited StatesNCT01507181

• KetamineCompleted
  Preventing Pain After Heart Surgery

  Phase 4Pain, Hyperalgesia, Chronic Illness150 participantsStart 2011-12

  Barts & The London NHS TrustUnited KingdomNCT01480765

• MDMACompleted
  Emotional Effects of Methylphenidate and MDMA in Healthy Subjects

  Phase 1Healthy16 participantsStart 2011-12

  University Hospital, Basel, SwitzerlandSwitzerlandNCT01465685

• KetamineTerminated
  Subanesthetic IV Bolus Ketamine in the Treatment of Acute Depression

  Phase 1Acute Depression20 participantsStart 2011-12

  United States Naval Medical Center, San DiegoUnited StatesNCT02378415

• KetamineCompleted
  Intranasal Ketamine in Treatment-Resistant Depression

  Major Depressive Disorder20 participantsStart 2011-10

  James MurroughUnited StatesNCT01304147

• KetamineUnknown
  A Study of Ketamine as an Antidepressant

  Phase 2Major Depressive Episode42 participantsStart 2011-09

  The University of New South WalesAustraliaNCT01441505

• MDMACompleted
  Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)

  Phase 1Mood Disorder, Substance-Related Disorders, Amphetamine-Related Disorders16 participantsStart 2011-07

  University Hospital, Basel, SwitzerlandSwitzerlandNCT01386177

• KetamineCompleted
  Ketamine Anesthesia in Electroconvulsive Therapy

  Depression38 participantsStart 2011-05

  Mayo ClinicUnited StatesNCT01367119

• KetamineCompleted
  Oral Ketamine for Control of Chronic Pain in Children

  Phase 1Chronic Pain12 participantsStart 2011-05

  University of RochesterUnited StatesNCT01369680

• MDMACompleted
  Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers

  Phase 1Psychological Effects of Study Drug107 participantsStart 2011-04

  Resilient PharmaceuticalsUnited StatesNCT01404754

• KetamineCompleted
  The Use of Ketamine as an Anaesthetic During Electroconvulsive Therapy

  Phase 4Depression40 participantsStart 2011-03

  University of AberdeenUnited KingdomNCT01306760

• KetamineCompleted
  Glutamatergic Modulation of Cocaine-related Deficits

  Phase 2Cocaine Dependence8 participantsStart 2011-02

  New York State Psychiatric InstituteUnited StatesNCT01790490

• MDMACompleted
  Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA)

  Mood Disorder, Substance-Related Disorders, Amphetamine-Related Disorders16 participantsStart 2011-01

  University Hospital, Basel, SwitzerlandSwitzerlandNCT01270672

• KetamineCompleted
  Neuromodulation to Facilitate the Effect of Ketamine

  Depression, Chronic Pain, Substance Abuse35 participantsStart 2011-01

  The Neuroscience Center, LLCUnited StatesNCT01816958

• KetamineCompleted
  Acute and Chronic Pain, Especially Neuropathic Pain, After Thoracotomy and Continuous Application of Ketamine.

  Acute Pain, Chronic Pain, Neuropathic Pain200 participantsStart 2011-01

  Dr. Horst Schmidt Klinik GmbHGermanyNCT03105765

• MDMACompleted
  Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial

  Phase 2Posttraumatic Stress Disorder3 participantsStart 2010-12

  Resilient PharmaceuticalsUnited StatesNCT01458327

• MDMACompleted
  Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

  Phase 2Posttraumatic Stress Disorder26 participantsStart 2010-11

  Resilient PharmaceuticalsUnited StatesNCT01211405

• KetamineTerminated
  N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression

  Phase 4Major Depressive Disorder17 participantsStart 2010-11

  Massachusetts General HospitalUnited StatesNCT01260649

• KetamineUnknown
  Oral Ketamine as an Adjuvant to Opioids for Pain Treatment in Cancer Patients

  Cancer, Pain, Tolerance50 participantsStart 2010-10

  Tel-Aviv Sourasky Medical CenterIsraelNCT01207206

• KetamineCompleted
  Evaluation of the Effect of Ketamine on Remifentanil-induced Hyperalgesia

  Phase 3Pain, Hyperalgesia, Inflammatory Response60 participantsStart 2010-09

  Federal University of São PauloBrazilNCT01301079

• MDMACompleted
  Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)

  Phase 1Mood Disorder, Substance-Related Disorders, Amphetamine-Related Disorders16 participantsStart 2010-07

  University Hospital, Basel, SwitzerlandSwitzerlandNCT01136278

• MDMACompleted
  Effects of MDMA on Social and Emotional Processing

  Drug Addiction65 participantsStart 2010-07

  University of ChicagoUnited StatesNCT01849419

• KetamineCompleted
  Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression

  Phase 4Unipolar Depression, Bipolar Depression31 participantsStart 2010-06

  Northwell HealthUnited StatesNCT01881763

• KetamineTerminated
  Study of Depression-Ketamine-Brain Function

  Phase 2Major Depression10 participantsStart 2010-06

  Markus KOSELSwitzerlandNCT01135758

• MDMACompleted
  Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.

  MDMA Discontinuation Syndrome12 participantsStart 2010-04

  California Pacific Medical Center Research InstituteUnited StatesNCT01053403

• KetamineCompleted
  Ketamine for Low Mood States in the ER

  Phase 1Depression, Suicide Ideation14 participantsStart 2010-04

  Yale UniversityUnited StatesNCT01209845

• KetamineTerminated
  Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression

  Major Depression, Bipolar Depression3 participantsStart 2010-04

  James MurroughUnited StatesNCT01309581

• KetamineCompleted
  Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)

  Phase 2Obsessive-Compulsive Disorder15 participantsStart 2010-04

  New York State Psychiatric InstituteUnited StatesNCT01100255

• KetamineCompleted
  Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia

  Phase 4Idiopathic Scoliosis, Spondylolisthesis54 participantsStart 2010-01

  Julia FinkelUnited StatesNCT01325493

• KetamineCompleted
  Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects

  Phase 1Depression128 participantsStart 2009-12

  AstraZenecaUnited KingdomNCT01046630

• MDMACompleted
  Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)

  Phase 1Mood Disorder, Substance-Related Disorders, Amphetamine-Related Disorders16 participantsStart 2009-11

  University Hospital, Basel, SwitzerlandSwitzerlandNCT00990067

• PsilocybinCompleted
  Psilocybin and Spiritual Practice

  Phase 1Healthy75 participantsStart 2009-08

  Johns Hopkins UniversityUnited StatesNCT00802282

• KetamineTerminated
  Treatment Study of Bipolar Depression

  Phase 4Bipolar Disorder1 participantsStart 2009-07

  Icahn School of Medicine at Mount SinaiUnited StatesNCT00947791

• Salvinorin ACompleted
  Placebo Controlled Study of Sublingual Salvinorin A

  Pharmaceutical Preparations8 participantsStart 2009-06

  California Pacific Medical Center Research InstituteNCT01149824

• MDMACompleted
  Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)

  Phase 1Mood Disorder, Substance-related Disorders, Amphetamine-related Disorders16 participantsStart 2009-04

  University Hospital, Basel, SwitzerlandSwitzerlandNCT00886886

• KetamineUnknown
  Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain

  Phase 3Cancer214 participantsStart 2009-04

  University of GlasgowUnited KingdomNCT01316744

• KetamineCompleted
  Oral Ketamine Administration in Patients With Peripheral Neuropathic Pain

  Phase 2Neuropathic Pain22 participantsStart 2009-03

  University Hospital, ToulouseFranceNCT00961194

• Salvinorin ACompleted
  Effects of Salvinorin A in Healthy Controls

  Early phase 1Healthy105 participantsStart 2009-02

  Yale UniversityUnited StatesNCT00700596

• PsilocybinCompleted
  Psilocybin Cancer Anxiety Study

  Early phase 1Cancer29 participantsStart 2009-02

  NYU Langone HealthUnited StatesNCT00957359

• MDMACompleted
  Role of Serotonin in Acute and Subacute MDMA Effects

  MDMA Mechanism of Action13 participantsStart 2009-02

  California Pacific Medical Center Research InstituteUnited StatesNCT00838305

• KetamineCompleted
  Ketamine Infusion for Obsessive-Compulsive Disorder

  Phase 2Obsessive-compulsive Disorder10 participantsStart 2009-02

  Yale UniversityUnited StatesNCT01349231

• KetamineCompleted
  Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)

  Phase 2Stress Disorders, Post-Traumatic, PTSD, Depression41 participantsStart 2009-01

  Dennis CharneyUnited StatesNCT00749203

• Salvinorin ACompleted
  Human Psychopharmacology of Salvinorin A

  Phase 1Healthy14 participantsStart 2008-11

  Johns Hopkins UniversityUnited StatesNCT00996411

• KetamineCompleted
  Optimization of IV Ketamine for Treatment Resistant Depression

  Phase 2Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)73 participantsStart 2008-11

  Baylor College of MedicineUnited StatesNCT00768430

• PsilocybinCompleted
  Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study

  Nicotine Dependence82 participantsStart 2008-09

  Johns Hopkins UniversityUnited StatesNCT01943994

• KetamineCompleted
  Effect of Ketamine on Opioid-Induced Hyperalgesia

  Pain, Chronic Pain, Hyperalgesia79 participantsStart 2008-09

  Massachusetts General HospitalUnited StatesNCT00833755

• KetamineTerminated
  Lidocaine and Ketamine Versus Standard Care on Acute and Chronic Pain

  Pain, Nausea12 participantsStart 2008-07

  The Cleveland ClinicUnited StatesNCT00720330

• KetamineUnknown
  Diabetic Neuropathy Topical Treatment

  Phase 3Diabetic Neuropathy, Pain200 participantsStart 2008-04

  Irmandade da Santa Casa de Misericordia de Sao PauloBrazilNCT00661063

• KetamineCompleted
  Neuropathic Pain Caused by Radiation Therapy

  Phase 3Neuropathic Pain Secondary to Radiation Therapy22 participantsStart 2008-04

  British Columbia Cancer AgencyCanadaNCT00798083

• KetamineCompleted
  Ketamine as an Anaesthetic Agent in Electroconvulsive Therapy (ECT)

  Phase 4Major Depressive Episode83 participantsStart 2008-04

  Northside Clinic, AustraliaAustraliaNCT00680433

• KetamineWithdrawn
  Ketamine Frequency Treatment for Major Depressive Disorder

  Phase 4Treatment Resistant DepressionStart 2008-03

  Essentia HealthUnited StatesNCT00646087

• LSDCompleted
  Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety

  Phase 2Anxiety12 participantsStart 2008-02

  Multidisciplinary Association for Psychedelic StudiesSwitzerlandNCT00920387

• KetamineCompleted
  Continuation Ketamine in Major Depression

  Phase 1Major Depressive Disorder36 participantsStart 2007-10

  James MurroughUnited StatesNCT00548964

• KetamineCompleted
  A Study of the Efficacy and Safety of Amitriptyline/Ketamine Topical Cream in Patients With Diabetic Peripheral Neuropathy

  Phase 2Diabetic Peripheral Neuropathy, Neuralgia226 participantsStart 2007-07

  EpiCept CorporationIndiaNCT00476151

• MDMATerminated
  Randomized Placebo-controlled Study of MDMA-assisted Therapy in People With PTSD - Israel

  Phase 2Posttraumatic Stress Disorder5 participantsStart 2007-05

  Resilient PharmaceuticalsIsraelNCT00402298

• KetamineCompleted
  Ketamine Associated With Opioids in Refractory Cancer Pain Treatment

  Phase 3Pain100 participantsStart 2007-05

  Assistance Publique - Hôpitaux de ParisFranceNCT00484484

• PsilocybinCompleted
  Psychopharmacology of Psilocybin in Cancer Patients

  Phase 2Depressive Symptoms, Anxiety, Cancer56 participantsStart 2007-04

  Johns Hopkins UniversityUnited StatesNCT00465595

• MDMATerminated
  MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer

  Phase 2Anxiety Disorder, Cancer2 participantsStart 2007-02

  Brigham and Women's HospitalUnited StatesNCT00252174

• KetamineCompleted
  Research Study for Major Depressive Disorder: Investigation of Glutamate Medications

  Phase 4Major Depression26 participantsStart 2006-12

  Baylor College of MedicineUnited StatesNCT00419003

• MDMACompleted
  Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder

  Phase 2Posttraumatic Stress Disorder14 participantsStart 2006-09

  Resilient PharmaceuticalsSwitzerlandNCT00353938

• KetamineSuspended
  Systemic Ketamine for the Improvement of Post-Operative Analgesia at the Alcohol-Dependent Patient

  Phase 3Alcoholic Patient, Carcinological Surgery ORL56 participantsStart 2006-04

  University Hospital, Clermont-FerrandFranceNCT00329394

• KetamineCompleted
  Rapid Antidepressant Effects of Ketamine in Major Depression

  Phase 1 / Phase 2Depression, Mood Disorders, Major Depresssion67 participantsStart 2004-07

  National Institute of Mental Health (NIMH)United StatesNCT00088699

• PsilocybinCompleted
  Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

  Phase 1 / Phase 2Anxiety12 participantsStart 2004-04

  Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterUnited StatesNCT00302744

• MDMACompleted
  MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder

  Phase 2Posttraumatic Stress Disorder23 participantsStart 2004-03

  Resilient PharmaceuticalsUnited StatesNCT00090064

• MDMACompleted
  Neurobiology and Pharmacokinets of Acute MDMA Administration

  Phase 1Substance-Related Disorders187 participantsStart 2004-02

  National Institute on Drug Abuse (NIDA)United StatesNCT01148342

• MDMACompleted
  -Methylenedioxymethamphetamine (MDMA, Ecstasy) Induced Changes in Drug Metabolism: Gender and Genetic Polymorphisms

  Phase 1Metabolism, Interaction27 participantsStart 2003-05

  Parc de Salut MarSpainNCT01447472

• MDMACompleted
  Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)

  Phase 1Mood Disorder, Substance-Related Disorders, Amphetamine-Related Disorders16 participantsStart 2001-06

  University Hospital, Basel, SwitzerlandSwitzerlandNCT00895804

• KetamineCompleted
  Ketamine/Placebo Family History Positive Study

  Alcoholism99 participantsStart 2001-03

  Yale UniversityUnited StatesNCT00588952

• KetamineWithdrawn
  Ketamine and Midazolam Infusions for CRPS: Feasibility Study

  Phase 2Complex Regional Pain Syndromes

  Stanford UniversityUnited StatesNCT05945147

• MDMAUnknown
  A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD

  Post Traumatic Stress Disorder

  Resilient PharmaceuticalsUnited StatesNCT04438512

• EsketamineUnknown
  Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)

  Depressive Disorder, Treatment-Resistant

  Janssen Research & Development, LLCNCT03829579